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Fear not O falcon bright,  
the gusty wind 'gainst your flight,  
That seeks to make you try,  
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Despite effective campaigns to reduce cigarette smoking, smoking 
remains a significant public health burden and one of the largest causes of death 
worldwide. It is estimated that in Europe and the Central Asia region, 122 
million people smoke, with a higher prevalence in males (56 %) than in females 
(17 %)
1
. In the United States, 40 % of 45 million smokers attempt to quit each 
year; however, only 3 % are successful
2
. The detrimental effects of smoking on 
physical health are widely publicized and well-understood. Recently, there is 
growing interest to investigate its effects on mental health. This interest is 
instigated by the strong empirical association of smoking with psychiatric 
disorders. The prevalence of smoking is higher among psychiatric patients than 
in the general population
3,4
. In a study assessing rates of smoking and smoking 
cessation in adults, it was found that respondents with a current mental illness 
had the highest current and lifetime smoking rates and lowest quitting rates 




Smoking-Psychopathology Association Studies 
 
Cross-sectional studies have indicated that smokers experience certain 
signs of depression such as sadness, hopelessness, or trouble sleeping more 
often than non-smokers
5,6
. Similarly, smokers are more likely to have higher 
rates of depressive symptoms than non-smokers
7,8
. Other studies have 
distinguished between current smokers, former smokers and never-smokers. In a 
report from the National Household Survey on Drug Abuse (NHSDA), current 
adolescent smokers had the highest odds of depressive symptoms, followed by 
former smokers, and then never-smokers
9
. Consistent with these findings in 




 have also found significant 
differences among current smokers, former smokers and never-smokers in their 
symptoms of depression. 
 
There seems to be a dose-response relationship between smoking and 
depression. Heavy smoking, as opposed to light smoking, is related to increased 
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severity of depressive symptoms
7, 10, 16, 17
. Similarly, the number of days smoked 
predicts depressive symptoms
8
. Many heavy smokers fulfill criteria for nicotine 
dependence. It is, therefore, not surprising that high levels of depressive 
symptoms are associated with nicotine dependence. In one study, it was found 
that as compared to non-dependent-, former, and never-smokers nicotine-




The smoking-anxiety association has received relatively little research 
attention. Regular smokers diagnosed with panic disorder have greater severity 
and intensity of anxiety symptoms than patients who do not smoke
19
. Similarly, 




Depression and anxiety disorders often co-occur. In a large population-
based survey of adults, depression was only marginally associated with smoking 
except in the presence of comorbid anxiety. Comorbid disorders had the 




Cross-sectional studies have also shown that the prevalence of smoking 
in depressed individuals is higher than in the general population. Depressed 
individuals are more likely to have ever smoked, and they are less successful in 
their attempts to quit smoking than those with no history of major depression
22
. 
Individuals with depressed mood, a history of major depression, or both 
conditions have greater likelihood of ever smoking and smoking initiation than 
never-depressed
23
 across all developmental stages. The prevalence of smoking 




Studies that examine smoking prevalence in individuals with anxiety 
disorders usually focus on patients with panic disorder. Zvolensky et al.
26
 put 
forward a theory suggesting that the association of smoking with anxiety 
disorders is specific to panic disorder and not generally to other anxiety 
disorders. To test this theory McCabe et al.
27
 examined smoking behaviors 
across three anxiety disorders and found that smoking prevalence was higher in 
patients with panic disorder than in patients with social phobia or obsessive-
Chapter 1 
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compulsive disorders. Moreover, patients with panic disorder were more likely 
to be heavy smokers. 
Developmental Pathways to the Co-occurrence of Smoking 
and Psychopathology 
 
Depression and Anxiety Preceding Smoking 
 
 The self-medication hypothesis posits that the motivation to continue to 
smoke is to alleviate depressive symptoms and so, depression is a predisposing 
factor in smoking initiation. This has been investigated in a number of 
longitudinal studies. For example, two six-wave longitudinal school-based 
studies found that depressive symptoms predicted later cigarette use
28, 29
. 
Another study found that adolescents with depressive symptoms were more 
likely to start smoking than those with no depressive symptoms
30
. These studies 
investigated the relation of smoking with depressive symptoms and not with a 
clinical diagnosis of depression, which also seems to be associated with 
smoking. For example, young people who met DSM-IV criteria for major 
depression were interviewed at 16, 18, and 21 years of age and were found to 




 Anxiety disorder as a predisposing factor in the onset of smoking has 
not been studied extensively. One population-based study found that non-
smokers and non-dependent smokers with social fears had increased odds of 




Few studies have assessed the role of both depressive and anxiety 
symptoms in smoking initiation. In a recent 10-year longitudinal school-based 
study, increasing severity of the symptoms of depression and anxiety in teenage 
was associated with an increased risk of nicotine dependence in young 
adulthood
33
. In a population-based study, it was found that pre-existing, 
currently active psychiatric disorders (unlike remitted disorders) including major 
depression and anxiety predicted subsequent onset of daily smoking and 
progression to nicotine dependence. Individuals with more than one pre-existing 
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disorder were at higher risk to starting smoking and progressing to nicotine 




Smoking Preceding Depression and Anxiety 
 
The role of smoking as a vulnerability factor in the development of 
depression has been examined in significant epidemiological investigations and 
population-based surveys using longitudinal design. The question of whether 
adolescent cigarette smoking predicts the development of depressive symptoms 
was addressed in a longitudinal follow-up survey of adolescents who were not 
depressed at baseline. Cigarette smoking was found to be the stronger 
determinant of developing depressive symptoms. Moreover, a dose-response 
relationship was observed between smoking level and depressive symptoms 
35
. 
In two large population-based studies on adolescents, smokers exhibited high 




Smoking is associated not only with elevated depressive symptoms but 
also with an increased risk of clinical depression as assessed according to DSM 
criteria. In population-based, longitudinal studies on adults, a strong association 
was found between smoking and subsequent depression
38, 39
. Furthermore, total 
smoking years and number of cigarettes smoked per day were associated with 
increasing risk of major depression 
38
. Another population-based prospective 
investigation revealed that pre-existing daily smoking predicted the onset of 
major depression, dysthymia, panic disorder, agoraphobia, alcohol- and drug-use 
disorders. Furthermore, independent of nicotine dependence, current smokers 
were more likely than former smokers to have subsequent onset of panic 




Investigating the Bi-directionality of Smoking-Depression / Anxiety 
Association  
 
Smoking and depression may mutually influence each other. A number 
of longitudinal studies have found a two-way temporal relation. For example, in 
adolescents, heavy and persistent smoking predicted increase in depressive 
Chapter 1 
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symptoms in a 1.5 year period after controlling for baseline depressive 
symptoms and other potential confounders; conversely, severe and persistent 
depressive symptoms predicted increases in smoking rates across the same time 
period after controlling for baseline smoking and other confounding variables
41
. 
In another longitudinal study it was found that never-smokers at follow-up (1 
year later) had lower depressive symptoms at baseline than those who were 
current or former smokers at follow-up. Baseline never-smokers with high 
depressive symptoms had a higher likelihood of being a smoker one year later. 
The study also found that current smokers and former smokers developed high 
depressive symptoms over time than never-smokers. Moreover, baseline never-
smokers who started smoking at follow-up had high depressive symptoms at 
both waves than baseline never-smokers and former smokers whose smoking 
status did not change at follow-up
42
. Consistently, history of major depression at 
baseline has increased the risk for progression to daily smoking and vice versa 
in a population-based study of young adults
43
. A history of major depression has 
increased the risk for progression to nicotine dependence. Similarly, a history of 
nicotine dependence was associated with first-incidence of major depression 





 Several longitudinal studies that examined two-way smoking-
depression temporal association found evidence for a uni-directional relation 
from smoking initiation to the development of depressive symptoms. For 
example, in one study, a one-way temporal relation was found; prior smoking 
was associated with a modest increased risk of subsequent depressed mood; 
however, prior depressed mood was not associated with a risk to starting 
smoking
45
. Similarly, in a large population-based study, it was found that at 1-
year follow-up, current  smoking was the strongest predictor of developing high 
levels of depressive symptoms; however, baseline high rates of depressive 
symptoms were not predictive of heavy smoking
46
. Similar uni-directional 





 was observed in other studies. 




Studies that investigated the directionality of smoking-anxiety 
association found a one-way temporal association from starting smoking to the 
onset or increasing risk of an anxiety disorder. No evidence for the reverse 
association, in which anxiety was a predisposing factor to start smoking, was 
found. Breslau and Klein
50
 found that daily smoking was associated with an 
increased risk of the first onset of panic attack, and the risk was higher in current 
than in former smokers. However, prior panic attacks did not predict the onset of 
daily smoking
50
. A similar pattern of uni-directional association between 
smoking and panic disorders was reported in a school-based study
51
. Cigarette 
smoking may also be associated with an increased risk of other anxiety 
disorders. In a 3-wave community-based prospective investigation of 
adolescents, it was found that heavy smoking during adolescence was associated 
with an increased risk of generalized anxiety disorder, agoraphobia and panic 
disorder during early adulthood after controlling for demographics, anxiety and 
depression during adolescence, alcohol and drug use, and parental smoking. No 
association of smoking with obsessive-compulsive disorder or social anxiety 
was found. Anxiety disorders during adolescence were not associated with 
starting smoking in young adulthood
52
. Another study found that regular 
smokers and nicotine-dependent smokers at baseline had an increased risk for 
new onset of panic attacks and disorder and other anxiety disorders except for 
generalized anxiety disorder and obsessive-compulsive disorder at a 4-year 
follow-up period; however, after controlling for comorbid disorders including 
depression, anxiety and substance-use disorders, smoking or nicotine 
dependence increases the risk of only panic attacks and disorders. Pre-existing 
panic attacks or disorder was not associated with subsequent smoking initiation 




Some studies investigated the temporal association of smoking with 
comorbid anxiety and depressive disorders. In a prospective population-based 
study, a bidirectional association between a mental disorder and smoking was 
found; starting smoking was associated with the subsequent first-ever incidence 
of generalized anxiety disorder and dysthymia, whereas generalized anxiety 
disorder was associated with subsequent onset of smoking
54
. In a 13-year 
Chapter 1 
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population-based study, nicotine-dependent young adults had elevated rates of 
anxiety and depression after controlling for history of mental health problems 
and other covariates. However, reduced mental health did not predict subsequent 
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Two different causal hypotheses have been put forward to explain these 
co-occurring conditions: (i) depression and anxiety disorders instigate smoking 
initiation, or maintain smoking behavior as a means of self-medicating negative 
affect
17, 56, 57
 which might be the result of neuropharmacological actions of 
nicotine in the brain leading to pleasure stimulation and the reduction of anxiety 
and tension
58
. This hypothesis is consistent with a finding that the level of 
monoamine oxidase B (which is inhibited or lowered by anti-depressants) is 
lower in the brains of smokers than in former smokers or non-smokers
59
; (ii) 
smoking initiation is temporally associated with the development of depression 
and anxiety disorders
60
 probably because of the effect of nicotine on the 
neurotransmission systems that are implicated in depression and anxiety 
disorders
61
. Studies that have found a dose-response relationship between 
smoking and the symptom severity of depression or anxiety disorders
7, 8, 10, 16, 17, 
20
, relatively high rates and symptoms of depression and/ or anxiety in nicotine-
dependent current smokers than non-dependent, former- or never-smokers
18, 44, 
55, 62-66
, higher rate of cigarette use and low mental health
67
, or longitudinal uni-
temporal association in either direction
28-40, 46-50, 52, 53, 55, 68
 can further support 
these causal hypotheses. 
Non-Causal Theories 
 
Non-causal theories have been suggested when a bidirectional 
association between smoking/ nicotine dependence and the affective disorders 
was found
41, 44, 54, 69, 70
. These theories have gained support from a number of 
twin studies that proposed that these co-occurring conditions can both be 
explained by shared genetic
71-75
 and environmental factors
71, 75-77
 that increase 
both smoking as well as depression risks, independent of each other. 
Chapter 1 
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Shared Vulnerability Factors Explaining Smoking-Depression / 
Anxiety Association 
 
As mentioned earlier, some longitudinal studies, that  investigated the 
nature of the direction of smoking-psychopathology association, found a bi-
directional temporal association in which smoking was associated with the onset 
of an affective disorder, and vice versa. These studies suggested the shared 
vulnerability hypothesis of smoking-psychopathology association, and 
conceptualized that common vulnerability factors might operate that reflect this 
association
44, 69
. This hypothesis has gained support from twin studies. In these 
studies evidence has been found for genetic and environmental factors 
accounting for the co-variation between depression and smoking. A prospective 
study on female twins tested both causal and non-causal models for evaluating 
smoking-major depression association. No direct causal relation in either 
direction was observed. However, controlling for the personal history of 
smoking and of major depression, a family history of major depression predicted 
smoking and a family history of smoking predicted major depression. 
Environmental factors also played some role which were mainly individual-
specific and had little in common. Thus the study supported the non-causal 
model whereby the comorbidity was mainly due to genetic factors
72
. Another 
study examined the relationship between depression, smoking and nicotine 
dependence in male twins and explored genetic and environmental influences. 
Genetic factors predisposed to both depression and smoking and nicotine 
dependence. The odds of smoking in co-twins of depressed probands was 
greater than those in which neither of the twins had a lifetime history of 
depression. Moreover, the non-depressed co-twins of the depressed probands 
reported more withdrawal symptoms and depressed mood after quitting
74
. After 
controlling for familial factors, that is, by using discordant twin-pairs, smoking 
remained a gender-sensitive predictor of depressive symptoms, thus supporting 
the causal association. However, after controlling for genetic factors, that is, by 
using monozygotic and dizygotic twin-pairs, the persistent smokers and the 
quitters among the monozygotic twin-pairs were at higher risk for depression 
than among the dizygotic twin-pairs. The stronger association in men was 
modestly accounted for by underlying shared genes
73
. Similarly, the question of 
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whether major depression, smoking and nicotine dependence share a common 
genetic and /or environmental liability, and whether there is a difference 
between these different trajectories of smoking, was addressed in another study. 
A non-causal association was found, which, in males, was entirely accounted for 
by shared underlying genes, whereas in females, both genetic and environmental 
liabilities accounted for this comorbidity
71
. Inconsistent with these findings, 
McCaffery and colleagues found that the significant association of current and 





 was predominantly influenced by non-shared  
environmental factors while in adolescent female twins
75
 both genetic and non-
shared environmental factors accounted for the co-variation. A study 
investigating the genetic and environmental liability factors of smoking-panic 
association in female twin-pairs found that panic attacks and lifetime smoking 




Other Risk Factors 
 
Other studies in general population and schools have found common 
risk factors that explain smoking-psychopathology association. For example, 
after controlling for the effects of demographic variables, comorbid depression, 
neuroticism, generalized anxiety disorder, and substance-use disorders, 
neuroticism was an independent predictor of the co-occurrence of smoking and 
panic attacks in adults
78
. A birth cohort was examined until the age of 16 years 
(N = 947), and it was found that significant associations between depressive 
symptoms and nicotine dependence were largely explained by common risk 
factors such as affiliation with deviant peers and lower self-esteem
63
. Another 
longitudinal investigation that followed students from teenage to young 
adulthood found that the association between smoking and panic attacks was no 
longer significant after adjusting for parental smoking and parental anxiety 
disorder
51
. Another risk factor explaining smoking-depression association was a 
history of conduct problems which was a predictor of both smoking and 






To explain conflicting findings in the literature regarding smoking-
depression association, Johnson et al.
79
 in a population-based sample of young 
adults tested Neale and Kendler’s
80
 etiological models of comorbidity for 
lifetime major depression and different smoking levels. The correlated liability 
model explained the comorbidity of depression with daily smoking, heavy 
smoking and nicotine dependence where familial liability explained the 
substantial amount of variance shared between depression and these levels of 
smoking; and in case of ever-smoking, it was associated with depression only 
when the smokers exceeded a higher threshold on the liability of smoking. Thus, 
depression is associated with regular (heavy) smoking, and ever-smokers would 
have depression only in case of heavy smoking. 
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Smoking-Depression / Anxiety Possible Linking 
Mechanisms 
 
To date, the mechanisms underlying the association of smoking with 





One possible mechanism linking smoking to an affective disorder may 
be BDNF Val
66
Met polymorphism. The BDNF gene which, in humans, is 
located on chromosome 11, encodes the BDNF protein
81
. The single nucleotide 
polymorphism (SNP) rs6265 in BDNF gene results in an amino acid Valine-to-








Met polymorphism in the brain-derived neurotrophic factor 
(BDNF) gene may be a plausible candidate gene polymorphism underlying 
smoking-depression/ anxiety association. An association of this polymorphism 
has been found with affective disorders
83-86
, and to some extent, with smoking
87, 
88




Several studies have supported the association of BDNF Val
66
Met 
polymorphism with clinical major depression. For example, Met
66
 carriers were 





studies that investigated the relationship of combination of gene markers 
including BDNF Val
66
Met polymorphism with depression, found that haplotype 
analysis of the combination of markers including BDNF rs6265 produced 
significant associations with major depression
83, 84, 86
. With the exception of one 
study in a community sample of children and adolescents
91
, no association of 
BDNF Val
66
Met polymorphism has been found with anxiety disorders including 




Though not extensively, the polymorphism has also been investigated in 
relation to addictive behaviors. Heroin-dependent individuals were more often 












 carriers were more likely to be 
current and former smokers than never-smokers
87
; however, a following study 
failed to replicate these findings
88
. A recent study with healthy Chinese male 
participants reported that smokers with the Met
66
 allele of the BDNF gene 






These studies indicate that BDNF Val
66
Met polymorphism may be 
involved in psychopathology and in addictive behaviors, however, there are 
some inconsistencies in findings, and the number of studies and sample size are 
small. Moreover, there is no study that has investigated smoking-
psychopathology association taking into account the role of this polymorphism. 
It has been suggested that gene-environment interaction studies may be more 
useful to elucidate the underlying molecular mechanisms that may explain the 
association between different phenotypes
96
. We investigate the smoking-
psychopathology association and examine the role of BDNF Val
66
Met 
polymorphism in this association. 
Serum Brain-Derived Neurotrophic Factor 
 
Another possible linking mechanism may be serum brain-derived 
neurotrophic factor (BDNF) which has been shown to be associated, both, with 
smoking and with depression and anxiety. BDNF is a small dimeric protein 
densely expressed in the central and the peripheral nervous system with high 
concentrations in the hippocampus and cerebral cortex
97, 98
. It is involved in the 
growth, development, survival, and function of neurons in the nervous system
99
. 
Animal studies have shown that stress decreases the expression of BDNF 
mRNA and protein in rat brain
100, 101
. Human postmortem studies have found 
reduced expression of BDNF mRNA and proteins in the brain of suicide victims 
diagnosed with different psychiatric disorders including depression, as 




Clinical studies have consistently reported the down regulation of serum 
BDNF expression with regard to depression. Various studies have shown that 
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depressed patients are characterized by lower serum BDNF levels than normal 
healthy controls
103-113
 and that, the severe the depressive symptoms, the lower 
the serum BDNF levels
104, 109, 111, 114-118





Given that depression and anxiety disorders are highly comorbid, and 
may share similar pathophysiological factors
121-124
, few studies have also 
investigated serum BDNF levels in patients with anxiety disorders. One study 
found lower baseline serum BDNF in patients with panic disorder as compared 
to normal controls
125
. A recent study reported gender-specific association of 
serum BDNF with anxiety: female patients diagnosed with anxiety had lower 
serum BDNF than female healthy participants, while no differences were found 
in male participants
126
. However, one study did not find significant difference in 
serum BDNF between patients with panic disorder and healthy participants
127
. 
Taken together, these preclinical and clinical studies adequately support the role 
of BDNF in the pathophysiology of depression and anxiety disorders. 
 
There is also an evidence of an association of serum BDNF with 
smoking/ nicotine exposure, however, research in this area is sparse. An animal 
study has found that the expression of BDNF mRNA and protein in the 
hippocampus of neonatal piglets is significantly increased following nicotine 
infusion
128
. Few studies in humans have also investigated an association of 
serum BDNF with smoking and nicotine dependence. With the exception of a 
small Japanese study (N = 29; 16 smokers)
129
, these studies have found that 




Given that smoking and nicotine dependence are highly associated with 
depression and anxiety disorders, there is reason to examine serum BDNF levels 
in relation to smoking/ nicotine dependence and depression/ anxiety. This issue 







Attentional bias in smokers to smoking-related cues has widely been 
documented, and it has been reported that smokers preferentially allocate their 
attention to such cues
132-151
. This attentional tendency has been thought to be 
important in maintaining drug-seeking behavior by enhancing the perception of 
drug-related cues in the environment, increasing drug-related cognitions for the 
cues and making it difficult to draw attention away from them; and because of 
the limited capacity of attention, the attentional resources left of competitive 
cues are depleted. The smoker may relapse to smoking after quitting because it 




The ability of an individual to use executive functioning to selectively 
keep focus on task-relevant stimuli and to inhibit interference from distracting 
stimuli has been termed as attentional control
153
. In high-anxious individuals, 
inhibiting processing of task-irrelevant threatening stimuli seems to be difficult 
as compared to low-anxious individuals
154
. Similarly, low attentional control is 
associated with distracting effect of task-irrelevant threat-related emotional 
cues
155-157
. These findings suggest that anxiety is associated with impaired 
inhibition, and that better attentional control might help reducing anxiety by 
disengaging a person’s attention from threat. 
 
Attentional control might be another possible mechanism linking 
smoking with negative mood. There is no study investigating the role of 
attentional control in smoking-psychopathology association. However, it can be 
speculated that smokers with better attentional control might be able to 
disengage their attention from smoking-related cues in the environment, and 
thus may be able to control their smoking urges which might help improve their 
mood states. 




Aims and Outlines of the Thesis 
 
The main objective of this thesis is to enhance our understanding of the 
association of smoking with depression and anxiety disorders, and to find 
possible explanations of this association. We used data from Netherlands Study 
of Depression and Anxiety, or NESDA
158
 to address our research questions 
regarding smoking-psychopathology association (chapter 2 to chapter 5). In 
chapter 6, we investigated the role of attentional control in attentional bias to 
smoking-related pictures. The data for this project were collected using the 
students of Leiden University. 
 
1. Given that early-age nicotine exposure has adverse effects on 





, Thapar et al.
161
), chapter 2, retrospectively, examines 
the association of smoking age-onset with the onset of 
depression and/ or an anxiety disorder. The chapter is based on 
the data of those psychiatric patients who developed depression 
and / or an anxiety disorder after they started smoking. 
2. In chapter 3, the severity and course of depressive and anxiety 
symptoms in never-smokers, former smokers, current smokers 
without nicotine dependence, and current smokers with 
nicotine dependence is investigated. The data of only those 
patients are used who had a current diagnosis (past 6 months) 
of an affective disorder. The chapter is based on baseline and 2-
year follow-up NESDA data. 
3. In chapter 4, the interaction between the BDNF gene Val
66
Met 
polymorphism and smoking status with symptom severity of 
depression and anxiety disorders is investigated. The data is 
based on the same NESDA sample that was used in chapter 3, 
that is, patients with a current diagnosis of an affective 
disorder. The sample is stratified into never-smokers, former 
smokers, and current smokers with and without nicotine 
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dependence. This chapter is based on the baseline NESDA 
data. 
4. Chapter 5 focuses on the association of serum BDNF with 
smoking or nicotine dependence in participants stratified 
according to their smoking status. The interaction of the BDNF 
gene Val
66
Met polymorphism and smoking status with serum 
BDNF is also examined. The analyses were controlled for the 
diagnosis of an affective disorder, as well as other demographic 
and health variables. 
5. In chapter 6, attentional bias across information processing 
phases, that is, the initial orienting and the maintenance phases 
of attention, and the role of attentional control in each of these 
phases is investigated using a dot-probe task with smoking-
related and neutral pictures in smokers and non-smokers. 
Participants are students from Leiden university with age range 
from 18 to 35 years. 
6. Finally, chapter 7 summarizes the main findings of the studies, 
discusses possible mechanisms, and provides clinical 
implications and future research directions.  
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Background. Smoking is a known risk indicator for depression and some of the 
anxiety disorders.  No data are available on the role of age at smoking onset in the 
development of depression and anxiety disorders. We examined the association of 
smoking onset age on the onset age of depression and anxiety disorders. 
 
Methods. Participants of the Netherlands Study of Depression and Anxiety 
Disorders (NESDA) who developed psychopathology after starting smoking were 
selected (N = 1,055). The dependent variable was the time to onset of 
psychopathology after starting smoking and the independent variable was age at 
smoking onset. 
 
Results. The time period between smoking onset and the onset of depression and/or 
anxiety disorders was five years shorter for early-onset smokers than for late-onset 
smokers. Moreover, a greater percentage of early-onset smokers than late-onset 
smokers had the first onset of psychopathology within the first five years after 
starting smoking. Age at smoking onset predicted age at psychopathology onset after 
controlling for the effects of gender, education and childhood trauma. When 
separate analyses were done for depression and anxiety disorders, this pattern of 
results was found only for anxiety disorders. 
 
Conclusions. A young age at smoking onset is associated with a shorter time to first 
onset of an anxiety disorder. This study with psychiatric patients extends previous 
findings in general population samples that smoking and depression and anxiety 
disorders are associated. 





Smoking-related physical health problems are well-documented and 
well-known. It is not generally known, however, that smoking is also associated 
with an increased risk of mental health problems, particularly anxiety disorders 
and depression. Cross-sectional studies have shown that smokers as compared to 
non-smokers are more likely to report anxiety and depressive symptoms
1-19
, a 
lifetime prevalence of major depression
15-17
 and comorbid anxiety and 
depression
11, 16
. These associations with psychiatric symptoms are evident in 
smokers even after statistically controlling for common confounding factors 
such as age, gender, race, parental education, marijuana use, alcohol use, 
cocaine dependence, parental smoking, increased work hours, unemployment, 
and social isolation
1, 3, 5, 7, 9
. 
 
Similarly, individuals with high depression and anxiety are significantly 
more likely to smoke
1, 20-26
 even after controlling for potential confounders such 
as gender, race, socioeconomic disadvantage, neuroticism, novelty seeking, 
childhood conduct problems, parental attachment, alcohol use, adverse life 
events, anxiety disorders, deviant peer affiliations, family instability, child 
abuse, and parental smoking
20, 21
. Smoking also appears to influence the severity 
of some anxiety disorders. Regular smokers with panic disorder report more 




Thus, the association of smoking with depression and anxiety disorders 
is well established in cross-sectional studies. However, uncertainty remains 
about the causal mechanisms of this association
20, 24
.Different hypotheses have 
been put forward to explain the high comorbidity between smoking and 
depression / anxiety disorders, each of which is supported by empirical evidence 
from longitudinal studies. The first hypothesis is that depression and anxiety 
disorders increase the likeliness of smoking initiation, or maintain smoking 
behavior. This hypothesis has gained support from a number of studies
28-34
. 
Some of these studies suggested that smoking may be used as self-medication
29, 
32, 34
 whereas others attributed the relation to peer influence




a temporal association exists between smoking and depression/ anxiety disorders 
in the direction from smoking initiation to the development of the disorder. 
Several longitudinal and retrospective cohort studies in adolescents and adults 
have demonstrated a strong association of starting smoking with an increased 
risk of developing depression
35-53
 and anxiety disorders, specifically panic 
attacks and disorder
37, 49, 51, 52
, agoraphobia
37, 52
 and generalized anxiety 
disorder
39, 52
. These studies support the hypothesis that smoking increases the 
risk of depression and anxiety. Some longitudinal studies, however, found a 
two-way temporal relation
39, 54-58
, suggesting that both conditions mutually 
influence each other. Thirdly, the comorbidity between smoking and depression 





Research on smoking age onset indicates that starting smoking at an 
earlier age is associated with health-related and behavioral problems later in life. 
For example, early-onset smoking as opposed to late-onset smoking is a stronger 
predictor associated with adverse physical health outcomes such as the 
development of peripheral artery disease
63
 and the risk of lung cancer
64
 later in 
life. Early-age smoking is also associated with deviant or atypical smoking 
patterns.  The earlier the age of onset of smoking, the higher the risk of regular 
smoking
65-67
, smoking more cigarettes per day
66-69
, decreased likelihood to 
quit
68, 70-73
, and nicotine dependence
74
. Some studies have reported that early-
onset smoking is associated with more health-risk behaviors. A study examining 
the relationship between early age of onset of cigarette, alcohol, marijuana, and 
cocaine and engagement in health-risk behaviors among middle school students, 
found a significant association between these variables, with the onset of 
cigarette use at 11 years or younger had the strongest association. However, this 
study is limited by its cross-sectional nature, so a causal relationship cannot be 
implied
75
. A five-year longitudinal study that investigated students from grade 7 
found that by grade 12, early smokers were more likely to have academic 
problems, and to be engaged in substance use and delinquent behavior than non-
smokers
76
. There is also evidence that early-onset/ adolescence smoking is 
associated with later substance use
77
 and the development of substance use 
disorders
78
, alcohol and illicit drug use, early pregnancy
79
, psychological and 










, however, lack a comparison group of 
late-onset smokers. This makes it difficult to say whether the problems were 
associated exclusively with early-onset smoking and not with late-onset 
smoking. Smoking in, both, adolescence and in adulthood is associated with 
depression and dysthymia, but only early-onset smoking is associated with 
bipolar disorders
82
. Early-onset smokers also have an increased prevalence of 
drug dependence
83
, alcohol abuse and dependence
67, 83
 than late-onset smokers. 





 states in adulthood than late-age nicotine 
exposure. It is not known, however, whether early-onset smoking as opposed to 
late-onset smoking is further associated with an increased risk of anxiety or 
depression in humans. 
 
In summary, the association of smoking with depression and some of 
the anxiety disorders is well-established. From longitudinal studies, it is evident 
that smoking has a temporal association with these disorders. In this article, we 
will focus on smokers who were non-depressed or -anxious when they started 
smoking. The main goal of the present study is to investigate whether a young 
age at smoking onset is associated with an early onset of anxiety and depression 
as compared to late-onset smoking. To our knowledge no studies in humans 
have been conducted that show the importance of early-age nicotine-exposure 
(as compared to late-age nicotine-exposure) in the development of depression 
and anxiety disorders. The primary hypothesis of this study is that the time to 
first onset of psychopathology (depression and/or anxiety disorder) and 
depression or anxiety disorders after starting smoking is shorter for early-onset 





Participants and Data 
 
Participants in the present study were drawn from an ongoing 8-year 
longitudinal naturalistic cohort study, the Netherlands Study of Depression and 
Anxiety (NESDA) which has started in September 2004 and investigates the 
long-term course and consequences of depression and anxiety disorders. 
NESDA includes 2,981 participants (66.4 % female) with the age range from 18 
to 65 years (Mean Age = 41.9 years; SD = 13.0). 
 
In order to represent various health care settings and developmental 
stages of psychopathology, NESDA recruited 19 % of the participants through 
the community settings, 54 % through primary care settings and 27 % through 
mental health care organizations. The community-based sample was based on 




, from previous 
studies. The primary care participants were recruited from 65 general 
practitioners in three research sites, Amsterdam, Groningen, and Leiden, 
through a 3-stage screening procedure consisting of the Kessler-10 questionnaire 
(K-10)
88
 and a telephone interview involving the short form of the Composite 
International Diagnostic Interview assessing major depressive disorder, 
dysthymia, generalized anxiety disorder, social phobia, agoraphobia, and panic. 
The participants from the mental health care were recruited from out-patient 
clinics around the three research sites, and they consisted of newly enrolled 
patients at these clinics. The diagnoses of depression and anxiety disorders were 
ascertained through a structured psychiatric interview (e.g., Mini International 
Neuropsychiatric Interview (MINI), and Structured Clinical Interview for DSM-
IV (SCID)). 
 
Of the 2,981 participants at baseline, 78 % had a lifetime depression 
and / or an anxiety disorder that included current diagnoses as well as diagnoses 
earlier in life, of which 57 % were diagnosed with current (six-month 
prevalence) anxiety or depressive disorder, 21 % with a remitted (lifetime but 
not current) anxiety or depressive disorder, and 22 % had no depression and/or 
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anxiety disorder. The general inclusion criterion was an age of 18 through 65 
years. Exclusion criteria were (i) a primary diagnosis of a psychotic disorder, 
bipolar disorder, obsessive-compulsive disorder, or addiction disorder and (ii) 
non fluency in Dutch language. 
 
The 4-hour baseline data were collected using self-report 
questionnaires, interviews, and a medical examination, a cognitive computer 
task, and collection of blood and saliva samples. The data was obtained on the 
presence, severity, and chronicity of anxiety and depressive disorders, as well as 
the demographic characteristics, psychosocial, psychological, physiological 
determinants, major life events, health behaviors including alcohol intake, 
smoking, drugs, physical activity and genetic measures of the participants. 
Further details about the NESDA design and sample can be found in Penninx et 
al.
89
. Ethical approval for the NESDA study protocol was obtained centrally 
from the Ethical Review Committee of the VU University Medical Center and 
locally from the review boards of each participating center. All participants 
signed informed consent. 
 
In the present study, only the participants (N= 1,055) who developed 
psychopathology, that is, anxiety disorders and / or depression, after starting 





Smoking behavior was measured by a self-constructed questionnaire 
including past and current smoking questions. Age at smoking-onset was 
defined as the age at which the respondents started smoking regularly. Two 
types of variables were created for age at smoking onset: a continuous variable 
(age in years) and a categorical variable that had two levels, early-onset smokers 
(10 - 15 years) and late-onset smokers (> 15 years). This represented a median 







The lifetime diagnoses and age at onset of depression and anxiety 
disorders (GAD, social phobia, agoraphobia, and panic) were ascertained using 
the lifetime version of the Composite International Diagnostic Interview (CIDI 
version 2.1)
90
. The CIDI is a structured interview designed to produce diagnoses 
of psychiatric disorders according to both the DSM-IV and the ICD-10 
definitions and criteria. The CIDI has high inter-rater reliability, high test-retest 
reliability and high validity for depressive and anxiety disorders
90, 91
. 





 Other covariates under study were gender, education, and childhood 
trauma. We included childhood trauma in the analysis because it was found to 
have an association with anxiety and depression
92
. Childhood trauma was 
assessed with the semi-structured Childhood Trauma Interview
93
. The 
participants were asked if they had any type of traumatic experience including 
emotional and/or psychological neglect, and physical and/or sexual abuse before 
age 16. These four kinds of childhood trauma were assessed by questions such 
as whether the participants had encountered any such experience caused by their 
natural or step parents, siblings, relatives, or somebody else before age 16. 
Participants answered “yes” or “no” to each category of childhood trauma; they 
also recorded the frequency of these trauma on a five-point scale: (1: once, 2: 
sometimes, 3: regular, 4: often, 5: very often). A cumulative index, childhood 
trauma index, was calculated consisting of sum scores of frequency ranging 




Preliminary analyses were conducted to ensure no violation of the 
assumptions of multivariate analysis. Multicollinearity, heterogeneity of 
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variance, normality of distributions, outlying scores, and coding errors were 
checked. 
 
First, the differences between early- and late-onset smokers on age, 
gender, education, and childhood trauma and lifetime diagnoses of depression 
and anxiety disorders were compared using independent-samples t-test and chi-
square test for independence. Cohen’s d and Phi coefficient were used to 
measure effect sizes for t-tests and chi-squares, respectively. Cohen’s d was 





Next, to see if there is a difference between the two groups in the time 
period between smoking onset and the onset of psychopathology, a t-test was 
carried out. Furthermore, two t-tests were run separately for (i) time period 
between smoking-onset to depression-onset, and (ii) time period between 
smoking-onset to anxiety-onset. Cases that developed depression after the onset 
of anxiety disorder were not included in the time-to-depression-onset analysis. 
Similarly, cases that developed an anxiety disorder after the onset of depression 
were not included in the time-to-anxiety-onset analysis.  Furthermore, we 
conducted two-way between-groups ANOVAs to examine gender differences on 
the time to the first onset of depression, and anxiety disorders in early- and late-
onset smokers. The significance level was set to .01 because the variance of the 
dependent variable across the groups was not equal. 
 
Finally, a hierarchical multiple linear regression analysis was conducted 
with the time between smoking onset and psychopathology onset as the outcome 
variable. The main predictor was the age at the onset of smoking. The model 
was adjusted for gender, education, and childhood trauma. Additionally, two 
similar regression analyses were conducted separately for depression and 






Of the 1,055 smokers (current and former smokers) who developed 
depression and / or anxiety disorders after starting smoking, 51.7 % were early-
onset smokers who started smoking before or at the age of 15 years. Table 1 
presents the demographic and clinical characteristics of the participants. The 
differences between early- and late-onset smokers on the clinical characteristics 
were statistically non-significant.  
 
Table 1. Participants characteristics stratified by age at the onset of smoking 
 










    
 N = 545 N = 510  
    
Age at baseline (Mean, SD) 42.0 12.3 47.1 11.1 -0.4*** 
Gender, F (%) 67.3  61.2  - 
Education (%)     - 
- basic 11.4  6.5   
- intermediate 62.6  61.8   
- high 26.1  31.8   
Childhood trauma (Mean, SD) 1.99 2.21 1.49 2.02 -0.12* 
Lifetime diagnosis (%)      
Anxiety 70.5  66.9  - 
- GAD 33.0  26.5  - 
- Social phobia 29.2  20.4  - 
- Panic      
-- without agoraphobia 12.8  17.3  - 
-- with agoraphobia 23.1  19.6  - 
- Agoraphobia 13.4  10.2  - 
Depression 84.4  81.8  - 
      
***p < 0.001; *p < 0.05 
a. 
Only significant results reported. 
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The groups differed significantly on age at baseline interview (p < 0.001) and 
childhood trauma (p < 0.05) with small effect size (Cohen’s d < 0.5). 
 
In early-onset smokers, the first diagnosis was made after a smaller 
number of years after starting smoking than in late-onset smokers (Table 2). 
Early-onset smokers developed their first disorder almost five years sooner than 
late-onset smokers (t (1015.2) = -8.02; p < 0.001; Cohen’s d = -0.5). Table 2 shows 
that 23.2 % of the early-onset smokers and 12.8 % of the late-onset smokers 
were diagnosed with a disorder within the first five years after starting smoking, 
and this difference was statistically significant (p < 0.05). Further, we conducted 
separate t-tests for depression and anxiety disorders (Table 2). Early-onset 
smokers developed an anxiety disorder approximately 4.5 year earlier than late-
onset smokers (t (597) = -5.72; p < 0.001; Cohen’s d = -0.5). However, depression 
was diagnosed only approximately 1.5 years earlier in early-onset smokers, and 
this difference was non-significant (t (640) = -1.89 ; p = 0.6). 
 
Three analyses of variance were run to see whether males and females 
differ in the number of years between the onset of the disorder and smoking. In 
the first ANOVA, the dependent variable was years to the onset of 
psychopathology (depression and/or anxiety). A significant main effect of 
gender (F (1, 1051) = 10.1; p = 0.002; partial η
2 
= 0.01) and smoking age onset (F 
(1, 1051) = 58.5; p < 0.001; partial η
2 
= 0.053) and a non-significant interaction 
effect of gender and smoking age onset (F (1, 1051) = 0.17; p > 0.05) was found. 
Estimated marginal means show that early-onset smokers developed 
psychopathology earlier (Mean = 9.9 years) than late-onset smokers (Mean = 
14.8 years). Similarly, females smokers (Mean = 11.4 years) were diagnosed 






Table 2. Mean (SD) of years to the onset of psychopathology after smoking 










      
Years to the onset of 
psychopathology 
9.7 9.3 14.6 10.5 -0.5** 
      
Years to the onset of depression
a
 14.1 10.9 15.7 10.4 - 
      




8.9 8.3 13.3 10.3 -0.5** 
      
Psychopathology diagnosis within 
5 years after starting smoking (% 
of the sample) 
23.2%  12.8%  * 
      
**p < 0.001; *p < 0.05 
a. 
Cases who developed only depression after starting smoking, or who developed 
both depression and anxiety disorders but depression preceded anxiety disorders. 
b. 
Cases who developed only anxiety disorders after starting smoking, or who 
developed both anxiety disorders and depression but anxiety disorders preceded 
depression. 
c. 
Only significant results reported. 
 
 A similar ANOVA with years to the onset of depression as the 
dependent variable revealed a significant main effect of gender (F (1, 638) = 23.9; 
p < 0.001; partial η
2 
= 0.04) and a non-significant main effect of smoking age 
onset (F (1, 638) = 1.38; p > 0.05). The interaction effect of gender and smoking 
age onset was also non-significant (F (1, 638) = 3.33; p > 0.05). Female smokers 
had their depression diagnosis earlier (Mean = 13.4 years) than male smokers 
(Mean = 17.6 years). Finally, an ANOVA with years to the onset of anxiety 
disorder was run. The main effect of smoking age onset was significant (F (1, 595) 
= 26.0; p < 0.001; partial η
2 
= 0.04). Early-onset smokers had an earlier onset of 
anxiety (Mean = 9.2 years) than late-onset smokers (Mean = 13.4 years). The 
main effect of gender and the interaction effect of gender and smoking age-onset 
did not reach significance (ps > 0.05). 




Last, a hierarchical multiple linear regression analysis was run. The 
outcome variable was the time to first onset of psychopathology after starting 
smoking. The predictor was age at the onset of smoking. Two models were 
fitted. The first model, including gender, education and childhood trauma, 
accounted for 2 % of the significant variance in the outcome variable (Table 3). 
The second model with gender, education, childhood trauma, and age at the 
onset of smoking explained 4 % of the total variance with 2 % additional 
variance being explained by age at the onset of smoking. Gender and age at the 
onset of smoking recorded significant beta values (p < 0.001); however, the 
highest beta value was obtained for age at the onset of smoking (beta = .14; p < 
0.001) (See table 3). 
 
Two additional regression analyses were run for depression and anxiety 
disorders separately. In the first regression analyses, participants who developed 
depression after they started smoking were selected; those participants who 
developed anxiety disorders before depression were excluded from the analysis. 
Two models were fitted. The outcome variable was time to the first onset of 
depression after starting smoking. The first model, adjusted for gender, 
education, and childhood trauma, explained 6 % of the variance in the outcome 
variable. The second model with smoking age onset as the predictor accounted 
for negligible amount of variance. Significant beta values were obtained for 




Table 3. Regression of age at smoking onset on the time between smoking 
onset and the onset of psychopathology 
 
  B SE β p 
      
 Years to the onset of psychopathology 
  
Model 1 Gender 2.4 0.6 .11 *** 
Education -0.1 0.1 -.03 0.3 
Childhood trauma -0.3 0.1 -.05 0.1 
Model 2 Gender 2.3 0.7 .11 *** 
Education -0.2 0.1 -.05 0.1 
Childhood trauma -0.2 0.1 -.04 0.2 
Age at smoking onset 0.4 0.1 .14 *** 
 Years to the onset of depression 
  
Model 1 Gender 4.2 0.9 .2 *** 
Education -0.3 0.1 -.1 * 
Childhood trauma -0.5 0.2 -.1 ** 
Model 2 Gender 4.2 0.9 .2 *** 
Education -0.3 0.1 -.1 * 
Childhood trauma -0.5 0.2 -.1 ** 
Age at smoking onset -0.1 0.1 -.02 0.6 
 Years to the onset of anxiety 
  
Model 1 Gender 1.9 0.8 .09 * 
Education -0.1 0.1 -.04 0.4 
Childhood trauma -0.2 0.2 -.04 0.3 
Model 2 Gender 1.7 0.8 .08 * 
Education -0.1 0.1 -.05 0.2 
Childhood trauma -0.1 0.2 -.02 0.6 
Age at smoking onset 0.4 0.1 .13 ** 
 
***p < 0.001; **p < 0.01; *p < 0.05 
 
In the second regression analyses, the participants who developed 
anxiety disorders after they started smoking were selected and those participants 
who developed depression before anxiety disorders were excluded from the 
analysis. Two models were fitted. The outcome variable was time to the first 
onset of anxiety disorders after starting smoking. The first model, adjusted for 
gender, education, and childhood trauma explained 1 % non-significant variance 
in the outcome variable. The second model with smoking age onset as the 
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predictor accounted for 3 % of the total variance with 2 % additional significant 
(p = 0.001) variance being explained by age at the onset of smoking. Gender (β 
= 0.08; p < 0.05) and age at smoking onset (β = 0.13; p < 0.01) recorded 





In this study, we investigated the relationship between age at smoking 
onset with the age at the onset of psychopathology in a large sample of smokers 
recruited from different settings. Although the study was cross-sectional and 
retrospective, we used a quasi-prospective design by selecting only the 
participants who started smoking before they were diagnosed with anxiety 
and/or depression. 
 
We found that in early-onset smokers the first diagnosis of depression 
and/or anxiety disorders was made significantly earlier than in late-onset 
smokers. When we run separate statistical tests for depression and anxiety 
disorder, we observed this pattern of results for anxiety disorder only. After 
starting smoking, anxiety disorder was diagnosed significantly earlier in 
smokers who started smoking early in their life. Both of these results were 
observed with moderate effect sizes. However, we found a non-significant 
relation of age at the onset of smoking and time to the onset of depression. 
 
We also found that female smokers developed depression and/or 
anxiety disorder, and depression alone, earlier than male smokers, though the 
strength of the association was not big. With respect to the diagnosis of anxiety 
disorders, there were no gender differences. 
 
Finally, regression analyses indicated that young age at smoking onset 
was the most powerful predictor of years to the onset of psychopathology. 
However, when separate regression analyses were conducted for depression and 
anxiety disorders, age at the onset of smoking significantly predicted only 
anxiety disorders. 
 
Our findings are consistent with the literature on the health effects of 
age at onset of smoking. For example, as opposed to late-onset smoking, starting 
smoking at an earlier age is associated with unfavorable physical health 
consequences
63, 64
. Early-onset smoking has also been reported to be associated 
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with later drinking problems. Grant
67
 found that early-onset smoking predicted 
lifetime drinking and the subsequent development of alcohol abuse and 
dependence. Further, early-onset smoking was associated with excessive alcohol 
consumption, alcohol disorders, and heavy and longer smoking as compared to 
late-onset smoking. Another study comparing the outcomes of smoking in 
adolescence versus in adulthood, found that both smoking groups showed a 
significant association with depression and dysthymia; however, only early-
onset smoking was associated with behavioral problems
82
. Similarly, early-onset 
smokers are more likely to be drug-dependent than late-onset smokers
83
. Given 
that smoking is often initiated in adolescence, it is surprising that despite the 
diverse empirical evidence of smoking-depression/anxiety link, the relation 
between early-onset smoking and depression/ anxiety disorders has not been 
addressed before in human studies. There are, however, some animal studies that 
have demonstrated that early-age nicotine exposure leads to behaviors that can 
be characterized as features of depression or anxiety disorders. For example, 
Iniguez et al.
85
 showed that nicotine exposure in rats led to increased sensitivity 
to aversive or anxiogenic stimuli and decreased sensitivity to rewarding stimuli. 
However, this state was observed only in rats that were exposed to nicotine 
during adolescence, and not in those exposed during adulthood. Similarly, rats 
that were exposed to nicotine as adolescents showed increased anxiety-like 




With small effect size, our finding that female smokers develop 
depression and anxiety disorder earlier than male smokers, is in agreement with 




In general, our findings extend previous research showing an 
association between smoking and a diagnosis of depression and/or anxiety 
disorders. In this association, age at smoking onset might be a crucial factor 
which has been overlooked in the research on smoking and depression or 
anxiety disorders. 
 
The mechanisms underlying the relation between early-onset smoking 
and psychopathology are unclear; however, a young and developing brain is 
Chapter 2 
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probably more sensitive to the detrimental effects of nicotine which manifests in 
adverse health outcomes later in life. This view is consistent with animal models 
showing that nicotine exposure in critical and early periods of brain 





 which may play a role in depression and anxiety 
disorders. 
 
There are several methodological limitations inherent to the study 
design that warrant consideration. The first and most important limitation is the 
cross-sectional nature of the study which makes it more difficult to investigate 
the temporal sequencing of smoking and depression/ anxiety disorders. Second, 
the data on age of onset of smoking, depression and anxiety disorders are based 
on retrospective reports of the participants and may be subject to recall bias. 
Thus it is difficult to determine precisely the onset-time of depression and 
anxiety disorders; however, we found a five year difference between early- and 
late-onset smokers which is unlikely to be due to recall bias. Third, the effect of 
pre-existing drug and alcohol use and other confounding factors, such as, 
nicotine dependence, was not controlled because data on age-onset of these 
variables were not available. Fourth, because the sample is pre-dominantly 
Dutch, therefore other ethnic groups were under-represented in our study. 
 
The current study, as an initial investigation of this association, 
provides an opportunity to stimulate longitudinal and prospective research on 
the relationship of early-onset smoking with depression and anxiety disorder. 
This study provides one more reason why smoking prevention and cessation 
programs should focus on children and adolescents. An important issue that may 
help improving these programs would be to elucidate the underlying 
mechanisms that link early-onset smoking and psychopathology. 
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Background. Previous research has indicated a strong association of smoking with 
depression and anxiety disorders, but the direction of the relationship is uncertain. 
Most research has been done in general population samples. We investigated the 
effect of smoking and nicotine dependence on the severity and course of depressive 
and anxiety symptoms in psychiatric patients. 
 
Methods. Data came from the Netherlands Study of Depression and Anxiety 
(NESDA) including participants with a current diagnosis of depression and/or an 
anxiety disorder (N=1,725). The course of smoking status and symptoms of 
depression, general anxiety, social anxiety, and agoraphobia were measured at 
baseline and after one and two years. Age, gender, education, alcohol use, physical 
activity, and negative life events were treated as covariates. 
 
Results. At baseline, the symptoms of depression, general anxiety, and agoraphobia 
were more severe in nicotine-dependent smokers than in never-smokers, former 
smokers, and non-dependent smokers. These differences remained after adjusting 
for covariates. Smaller differences were observed for severity of social anxiety 
which were no longer significant after controlling for covariates. Over a two-year 
follow-up, the improvement of depressive and anxiety symptoms was slower in 
nicotine-dependent smokers than in the other groups even after controlling for 
covariates. There were no differences between the groups in the course of symptoms 
of social anxiety and agoraphobia over time.  
 
Conclusions. In psychiatric patients, smoking is associated with higher severity of 
depressive and anxiety symptoms, and with slower recovery, but only when smokers 
are nicotine-dependent.  
 
 










 has been well-established in epidemiological research. 
Cross-sectional studies have indicated an elevated level of depressive and 
anxiety symptoms in smokers than in never- and former smokers
3, 4, 8, 10-17
. 
Furthermore, successful quitters have fewer depressive symptoms and lifetime 
depression and anxiety diagnoses than unsuccessful quitters and current 
smokers
18
. However, smokers meeting criteria for major depression have a 
harder time quitting and are more likely to be heavy smokers
19
. The severity of 
symptoms is related to the number of cigarettes smoked per day or heavy 
smoking
13, 20, 21
 and number of days smoked
12
. Further, nicotine-dependent 
smokers have more severe depressive and anxiety symptoms than non-
dependent smokers
1, 4, 22
. Recurring depression is associated with worst 
smoking-related behaviours than a single episode or a history of depression. For 
example, smokers with recurrent episodes of major depression smoked more 
cigarettes, were nicotine-dependent more often and reported fewer quit attempts 
than never-depressed smokers. Those with a single episode were 
indistinguishable from the never-depressed smokers on most parameters, 
including lifetime cessation attempts
23
. A meta-analysis revealed that a history 





Cross-sectional studies have also indicated a high prevalence of current 
smoking in individuals with lifetime depression, anxiety, or comorbid 
depression and anxiety
7, 25-30
 than in the general population. Smoking prevalence 
is higher among severely depressed than among mildly and moderately 
depressed patients
31
. These associations of smoking with depressive/anxiety 
disorders remain even after controlling for potential confounders such as socio-
demographic variables, substance use/dependence, increased work hours, social 
isolation, neuroticism, novelty seeking, childhood conduct problems and 
childhood abuse, adverse life events, parental smoking history, deviant peers, 
family instability and anxiety disorders





The direction of causality of smoking-psychopathology association has 
not yet been fully understood
35
. Longitudinal studies have attempted to explain 
the mechanisms of the association by charting the timeline of smoking 
behaviour and depression/anxiety disorders. Several studies have demonstrated 




, and social fears 
and social phobia
9
 increase the likelihood of starting smoking and progression to 
nicotine dependence
33
. These results lead to the assumption that smoking may 
serve as self-medication to ameliorate negative symptoms
42
. Other studies have 
found that smoking is a vulnerability factor in the development of depression / 
anxiety disorders
5, 32, 43-47
. Furthermore, nicotine-dependent smokers have more 
severe depressive and anxiety symptoms than non-dependent smokers in a 13-
year longitudinal study
48
. Thus, these data lead to the assumption that smoking 
has a predictive role in the onset or increasing severity of these disorders
5
. 
Several longitudinal studies have found evidence for a bidirectional smoking-
depression/anxiety relationship
2, 6, 48-58
 in which the two conditions mutually 
influence each other. Finally, these co-occurring conditions may also be 
explained partly by common environmental
59, 60
 and genetic factors
61-64
. [For 
further details, interested readers may refer to reviews on smoking and co-




In summary, the associations of smoking with depression and anxiety 
are well-established. Longitudinal studies suggest that this association is 
bidirectional. Moreover, the rates of depression and anxiety disorders are higher 
in current smokers, particularly in heavy, nicotine-dependent smokers and, 
comparatively lower symptoms have been observed in former smokers. Most of 
the studies in this area are conducted in non-clinical samples drawn from the 
general population or schools, and mainly focus on smoking behavior. The 
effect of nicotine dependence has been given relatively little research attention. 
Further, the majority of these studies look at sub-threshold symptoms, and not at 
diagnoses, of depression and anxiety disorders.  
 
In the present study, we will examine the severity and course of 
depressive and anxiety symptoms over two years in smokers (non-dependent, 
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nicotine-dependent) and non-smokers (never-smokers, former smokers) with a 
current diagnosis of depressive and/or an anxiety disorder. We hypothesize that: 
(i) the symptoms of depression and anxiety would be more severe in nicotine-
dependent smokers than in non-dependent smokers, who would have more 
severe symptoms than former smokers and never-smokers, and (ii) the rate of 
improvement of anxiety and depressive symptoms would be slower in current 





Participants and Data 
 
The data came from an on-going naturalistic cohort study, the 
Netherlands Study of Depression and Anxiety (NESDA), started in September 
2004, and investigates the long-term course and consequences of depression and 
anxiety disorders. The baseline NESDA sample includes 2,981 participants (age 
range: 18-65 years; 66.4 % females), consisting of persons with a current 
depression and / or anxiety disorders (57 %), persons with a remitted history of 
the disorders (21 %) and healthy controls (22 %). Exclusion criteria were (i) a 
primary diagnosis of a psychotic disorder, addiction disorder, obsessive-
compulsive disorder, or bipolar disorder, and (ii) non-fluency in Dutch. 
Participants were recruited from the community, general practice settings and 
mental health care organizations. The baseline data were collected using self-
report questionnaires, interviews, a medical examination, a cognitive computer 
task, and collection of blood and saliva samples. Data were obtained on the 
presence, severity, and chronicity of anxiety and depression, as well as the 
demographic characteristics, psychosocial, psychological, physiological 
determinants, life events, health behaviors including alcohol intake, smoking, 
drugs, physical activity and genetic measures of the participants. Ethical 
approval for NESDA was obtained from the ethical review boards of 
participating centers, and all participants signed informed consent [for full 




Depressive and anxiety symptoms were assessed again after one year 
(response rate = 82 %) and then after two years (response rate = 87.1 %). In the 
present study, only the participants currently diagnosed (past 6 months) with 
depression and / or anxiety disorders at the baseline assessment were selected (N 
= 1,725); healthy controls (N = 661) and remitted depressed participants (N = 
595) were excluded. We used baseline, 1-year and 2-year data of all the 
variables included in the analyses: smoking status, confounding variables, and 
severity of symptoms of depressive and anxiety disorders.  




Those dropped out from the current analyses (16.4 %) were 
significantly younger, had experienced more negative life events (ps < 0.05; 
Cohen’s ds ≤ 0.2), and had higher symptoms of depression, anxiety (ps < 0.001; 
Cohen’s d = 0.3) and agoraphobia (p < 0.01; Cohen’s d = 0.2) than those in the 
study. However, no differences were found in alcohol consumption and 
symptoms of social anxiety (ps > 0.05). Similarly, the drop-outs were not 
different in gender distribution (p > 0.05) from those in the study. However, they 
had significantly low education and low physical activity (ps > 0.05) than those 





 Participants were classified into current smokers (nicotine-dependent 
and non-dependent), former smokers, and never-smokers. Former smokers were 
those who had stopped smoking definitively, and never-smokers were those who 
never smoked during their lifetime. The Fagerstrom test for nicotine dependence 
(FTND) was used to assess nicotine dependence
68
 in current smokers only. The 
reliability and internal consistency of FTND have been found to be adequate in 
previous research
69
. The FTND assesses daily smoking rate, interval between 
waking up and the first cigarette, frequency of smoking after waking up, 
difficulty refraining from smoking in places where it is forbidden, and despite 
medical illness, and also difficulty giving up the first cigarette in the morning. 
The sum score of FTND can range from 0 to 10. Current smokers with a score 
of 4 or higher on the FTND in the present study were defined as nicotine-
dependent smokers
48, 70, 71
. Nicotine-dependent smokers were daily smokers who 
smoked on daily, regular basis. Of the non-dependent smokers, 87 % were daily 
smokers, smoking between 1 and 30 cigarettes per day, and the remaining 13 % 
smoked less than 7 cigarettes per week. Smoking status of the participants was 
relatively stable from baseline to wave 3. Never- and former smokers at baseline 
did not change their smoking status at wave 3. Of the total study sample, 3.2 % 
non-dependent smokers (N = 55) and 1.3 % dependent smokers (N = 22) quit 






The lifetime diagnoses and age at onset of depression and anxiety 
disorders were ascertained using the Composite International Diagnostic 
Interview (CIDI v2.1). The CIDI is a structured interview designed to assess 
diagnoses of psychiatric disorders according to DSM-IV criteria. The CIDI has 
high inter-rater reliability, high test-retest reliability and high validity for 




Depressive symptoms were assessed by the 30-item self-report 
Inventory of Depressive Symptomatology (IDS; score range: 0-84) which has 
shown high correlations with observer rated scales
73
. The 21-item Beck Anxiety 
Inventory (BAI; score range: 0-62), was used to assess anxiety symptoms
74
 
whereas the symptoms of fear were measured with the 15-item Fear 
Questionnaire
75
. In our analyses, we used two subscales of Fear Questionnaire
75
; 
(i) FQ items for social anxiety symptoms, and (ii) FQ items for agoraphobia 
symptoms. Both subscales have sufficient internal consistency
76
, and the total 
score of each subscale ranges from 0 to 40. 
 
Potential confounding variables 
 
The Alcohol Use Disorder Identification Test (AUDIT; range: 0-40) 
was used to assess alcohol intake
77
. The International Physical Activity 
Questionnaire (IPAQ) was used to assess self-reported physical activity. IPAQ 
estimates weekly energy expenditure based on daily physical activities
78
. 
Negative life events in the past year were assessed with the Brugha 
questionnaire
79
. Other covariates under study were age, gender and education. 
Statistical Analyses 
 
Data were screened for accuracy, outlying scores, and the assumptions 
of univariate and multivariate analysis. First, we evaluated baseline differences 
among nicotine-dependent and non-dependent smokers, former smokers, and 
never-smokers on the socio-demographic variables and health behaviors using 
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one-way analyses of variance (ANOVA) with post hoc tests and chi-square tests 
for independence. Eta squared and Cramer’s V were used as measures of effect 
size for ANOVA and chi-square, respectively. Then, the cross-sectional 
associations of smoking with depressive and anxiety symptoms were examined 
using a one-way multivariate ANOVA. Four dependent variables were the severity 
of symptoms of depression, anxiety, social anxiety and agoraphobia. The 
independent variable was smoking status. Multivariate ANOVA was followed 
by one-way ANOVAs with post hoc comparisons. Next, we performed four 
hierarchical multiple linear regressions to assess the association between 
smoking status and severity of the disorders while controlling for confounding 
variables. In each of the regression analyses, we fitted four models. In the first 
model, we entered age, gender, and education; the second model added negative 
life events and alcohol use to the previous model; similarly, in the third and 
fourth models, we added physical activity and smoking status, respectively, to 
the previous models. Thus the estimates provided from the final model include 
all variables. 
 
Finally, to evaluate the change in the severity of the disorders in the 
four groups over time linear mixed models (LMMs) were built. The outcome 
variables were the severity of the symptoms of depression, anxiety, social 
anxiety, and agoraphobia. Smoking status was modeled both as a fixed factor 
and a random factor. The fixed effect of smoking status is the average effect in 
the entire study population, expressed by the regression coefficient. The random 
effect is specified to investigate group differences on severity of symptoms as it 
is assumed that the effect varies randomly within the participants. The covariates 
gender, education, and negative life events were modeled as fixed factors, while 
age, alcohol use and physical activity as random factors. In NESDA, the data on 
smoking status are available at baseline and at follow-up; however, the FTND 
data are available only at baseline. So while constructing the data file for LMM, 
we considered the participants as nicotine-dependent at follow-up if they were 
dependent at baseline. However, if they quit between baseline and follow-up 
period, they were grouped into former smokers. The parameters were estimated 
with maximum likelihood (ML) technique. We specified the unstructured 
repeated and random-effects covariance type because it imposes the fewest 
Chapter 3 
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assumptions and comparatively, a better fit of the model. Linear mixed model 
approach was preferred over repeated measures ANOVAs to analyze 
longitudinal data because (i) unlike repeated measures ANOVA, LMMs can 
fully accommodate unbalanced data sets resulting from missing data, common 
with longitudinal studies; (ii) repeated measures ANOVA requires all 
participants to be assessed at the same time point, and to have exactly the same 
number of observations, which is hardly possible in case of longitudinal study. 
LMMs can analyze such unbalanced data sets easily
80
. Analyses were run in 
PASW (V. 17.0) for windows. 






Table 1 presents the socio-demographic and health behavior 
characteristics of the participants at baseline. The groups differed significantly 
in age (F (3,1721) = 37.9; p < 0.001) and alcohol use (F (3,1695) = 39.4; p < 0.001) 
with medium effect size (η
2 
= 0.06). The groups also differed statistically in past 
year negative life events (F (3,1721) = 5.1; p < 0.01) with small effect size (η
2 
= 
0.01). Post hoc comparisons using the Tukey HSD indicated that former 
smokers were significantly older than nicotine-dependent smokers and both 
were older than never-smokers and non-dependent smokers (Table 1). Former 
smokers consumed significantly more alcohol than never-smokers, however, 
when compared with current smokers they used significantly less alcohol (ps < 
0.001). Both current smoking groups were not significantly different from each 
other in alcohol use (p > 0.05). Similarly, former smokers reported fewer 
negative life events than current smokers (both groups) (p < 0.05) and never-
smokers were not different than any of the groups in life events (p > 0.05). A 
chi-square test indicated that at baseline, the groups differed significantly in 
gender (χ2 (3) = 7.9; p < 0.05), education (χ2 (6) = 63.0; p < 0.001), and 
physical activity (χ2 (6) = 30.7; p < 0.001) with small to medium effect sizes 
(Table 1). The groups also differed significantly in the prevalence of current 
diagnoses of depression (χ2 (3)=14.6; p < 0.01), generalized anxiety disorder (χ2 
(3)=29.9; p < 0.001), and panic with agoraphobia (χ2 (3)=25.2; p < 0.001). 
However, no significant group differences were found (ps > 0.05) in the current 







Table 1. Baseline demographic and health behavior characteristics of the participants 
     
Sociodemographic 


















 N= 438 N= 527 N= 411 N= 349 
      




38.5 (11.9) 41.6 (11.0) 0.06*** 
Gender, F (%) 70.1 66.2 69.1 61.3 0.07* 
Education (%)     0.14*** 
- basic 6.6 6.5 5.4 16.3  
- intermediate 61.0 57.9 67.4 65.6  
- high 32.4 35.7 28.2 18.1  
Alcohol intake(Mean, SD) 2.9 (3.5) 4.6 (4.6) 6.3 (5.5) 6.2 (6.7) 0.06*** 
Physical activity (%)     0.09*** 
- low 16.9 16.9 18.7 29.0  
- moderate 43.2 35.9 37.7 31.6  
- high 40.0 47.1 43.6 39.4  
Stressful events (Mean, SD) 0.7 (1.0) 0.6 (0.9) 0.8 (1.2) 0.8 (1.1) 0.01** 
      
Current diagnoses (%)      
Anxiety 73.5 73.8 76.6 79.9 ns 
- Generalized anxiety 30.4 18.6 28.0 33.8 0.13*** 
- Social anxiety 36.3 38.1 36.7 44.1 ns 
- Panic      
-- without agoraphobia 15.5 12.1 16.5 13.5 ns 
-- with agoraphobia 18.0 22.0 28.5 31.8 0.12*** 
- Agoraphobia 9.8 13.9 8.8 10.0 ns 
Depression 71.9 63.2 66.7 73.9 0.10*** 
      
***p < 0.001; **p < 0.01; *p < 0.05 
a
 Effect size of only significant results reported 
 
Symptom Severity at Baseline 
 
A multivariate ANOVA indicated a significant difference among 
groups on a linear combination of the dependent variables (F (12,5076) = 7.45; p < 
0.001; Pillai’s Trace = 0.05; partial η
2
= 0.02). All four dependent variables 
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reached statistical significance: severity of depression (F (3,1693) = 18.4; p < 
0.001; partial η
2 
= 0.03); anxiety (F (3,1693) = 20.9; p < 0.001; partial η
2 
= 0.04); 
social anxiety (F (3,1693) = 4.2; p < 0.01; partial η
2 
= 0.01); agoraphobia (F (3,1693) 
= 13.2; p < 0.001; partial η
2 
= 0.02). Tukey HSD revealed that on three of the 
dependent variables (severity of depression, anxiety and agoraphobia) nicotine-
dependent smokers had higher scores than non-dependent smokers, former 
smokers and never-smokers (ps < 0.001). The latter three groups were not 
different from each other on these variables (ps > 0.05). For the severity of 
social anxiety, results were slightly different. Nicotine-dependent smokers were 
more socially anxious than former smokers (p < 0.05) and non-dependent 
smokers, but they were not different from never-smokers (p > 0.05). The mean 
scores are presented in table 2. We also repeated similar analyses by combining 
the two groups of current smokers and found that current smokers had 
significantly more severe depressive and anxiety symptoms than former and 
never-smokers (p < 0.001), except for social anxiety symptoms.
1
  
                                                 
1
 The demographic characteristics and severity of symptoms of the total sample of 
this study, and that of the combined current smoking groups can be viewed as 





Table 2. Mean (SD) severity of the symptoms in participants stratified by 
smoking status at baseline 






















28.0 (12.4) 33.3 (12.6) 0.03*** 





15.3 (9.6) 16.8 (11.0) 20.9 (11.5) 0.04*** 
      
Symptoms of 
social anxiety 
15.1 (8.8) 14.4 (8.8) 14.3 (8.6) 16.4 (9.7) 0.01** 
      
Symptoms of 
agoraphobia 
8.8 (9.0) 8.7 (8.8) 9.3 (9.4) 12.6 (10.9) 0.02*** 
      
***p < 0.001; **p < 0.01 
 
 Finally, four regression analyses were run. In the regression analysis 
with symptoms of depression as the dependent variable, the overall variance 
explained was 8.4 % (p < 0.001). The regression analysis with symptoms of 
anxiety as the dependent variable explained 8 % of the significant overall 
variance (p < 0.001). Similarly, for the symptoms of social anxiety and 
agoraphobia, the overall variance explained was 2.3 % (p < 0.05) and 7.4 % (p < 
0.001), respectively. For individual contribution of each variable in predicting 
symptom severity, see table 3.2 
                                                 
2
 The regression analyses with continuous baseline FTND score for all four 
dependent variables can be viewed as supplementary material by accessing the 
online version of this paper. 




Table 3. Regression of smoking status on the severity of the disorders 
 B SE β p 
 Severity of depression 
Age 0.06 0.03 0.06 * 
Gender 0.04 0.64 0.002 ns 
Education -0.61 0.09 -0.16 *** 
Stressful life events 0.87 0.28 0.07 ** 
Alcohol intake -0.05 0.06 -0.02 ns 
Low vs. moderate physical activity -2.22 0.82 -0.09 ** 
Low vs. high physical activity -3.80 0.80 -0.15 *** 
Never-smokers vs. current smokers (nD)
 †
 -1.15 0.86 -0.04 ns 
Never-smokers vs. current smokers (D)
 †
 2.81 0.91 0.09 ** 
Never-smokers vs. former smokers -2.06 0.81 -0.08 * 
 Severity of anxiety 
Age 0.02 0.02 0.03 ns 
Gender 0.98 0.56 0.04 ns 
Education -0.59 0.08 -0.18 *** 
Stressful life events 0.57 0.24 0.06 * 
Alcohol intake -0.02 0.05 -0.01 ns 
Low vs. moderate physical activity -1.31 0.71 -0.06 ns 
Low vs. high physical activity -1.80 0.69 -0.08 ** 
Never-smokers vs. current smokers (nD)
 †
 0.64 0.74 0.03 ns 
Never-smokers vs. current smokers (D)
 †
 3.80 0.79 0.14 *** 
Never-smokers vs. former smokers -0.71 0.70 -0.03 ns 
 Severity of social anxiety 
Age -0.01 0.02 -0.01 ns 
Gender 1.35 0.48 0.07 ** 
Education -0.25 0.07 -0.09 *** 
Stressful life events -0.02 0.21 -0.002 ns 
Alcohol intake 0.07 0.05 0.04 ns 
Low vs. moderate physical activity -0.33 0.61 -0.02 ns 
Low vs. high physical activity -1.21 0.59 -0.07 * 
Never-smokers vs. current smokers (nD)
 †
 -0.97 0.64 -0.05 ns 
Never-smokers vs. current smokers (D)
 †
 0.83 0.68 0.04 ns 
Never-smokers vs. former smokers -0.64 0.60 -0.03 ns 
 Severity of agoraphobia 
Age 0.02 0.02 0.03 ns 
Gender 2.04 0.49 0.10 *** 
Education -0.51 0.07 -0.17 *** 
Stressful life events -0.09 0.22 -0.01 ns 
Alcohol intake -0.08 0.05 -0.05 ns 
Low vs. moderate physical activity -0.91 0.63 -0.05 ns 
Low vs. high physical activity -1.32 0.61 -0.07 * 
Never-smokers vs. current smokers (nD)
 †
 0.67 0.66 0.03 ns 
Never-smokers vs. current smokers (D)
 †
 3.32 0.70 0.14 *** 
Never-smokers vs. former smokers 0.28 0.62 0.01 ns 
***p < 0.001; **p < 0.01; *p < 0.05; ns=non-significant 
† 





We carried out similar regression analyses by including baseline FTND 
score as continuous covariate. A significant positive linear relationship between 
FTND and severity of symptoms on all four measures were found, thus 
confirming our initially reported analyses (Table 3S).
2
 
Smoking Status and the Course of Depression and Anxiety 
 
 The severity of depressive and anxiety symptoms in the participants 
over time was evaluated with linear mixed models. The intercept and linear 
slope parameters were statistically significant (ps ≤ 0.001), indicating a 
significant between-participants variation in the initial status of the dependent 
variable and linear growth rate (Table 4). The symptoms of depression, anxiety, 
social anxiety, and agoraphobia decreased over time in all four groups. 
However, we found statistically significant interaction of time with the 
symptoms of depression and anxiety only for nicotine-dependent smokers (ps < 
0.05) suggesting that depressive and anxiety symptoms of dependent smokers 
improved more slowly as compared with the other three groups (Table 4). Social 
anxiety and agoraphobia symptoms decreased over time, but none of the 
smoking groups improved faster or slower than any of the other groups (ps > 
0.05). 
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 Symptoms of 
depression 




         
 β 95% CI β 95% CI β 95% CI β 95% CI 
         
Intercept 38.4 24.3 , 52.4*** 23.0 11.6, 34.5*** 18.0 5.4, 30.5* 16.5 6.2, 26.8** 
Time -3.9 -4.6 , -3.1*** -1.9 -2.5, -1.3*** -1.3 -3.0, 0.4 -0.9 -1.5, -0.4** 
Never-smokers 0  0  0  0  
Former smokers -2.8 -16.0, 10.4 -1.3 -12.4, 9.8 -2.4 -11.9, 7.1 0.8 -8.3, 9.9 
Current smokers (nD)
 †
 -3.2 -15.8, 9.5 -1.8 -12.2, 8.5 -3.0 -12.7, 6.7 -0.7 -9.9, 8.5 
Current smokers (D)
 †
 1.4 -12.0, 14.7 1.4 -9.3, 12.1 -0.7 -10.5, 9.0 3.4 -6.6, 13.4 
         
Interaction with time         
         
Never-smokers 0  0  0  0  
Former smokers 0.2 -0.6, 1.1 0.05 -0.7, 0.8 0.07 -1.4, 1.5 -0.3 -0.9, 0.3 
Current smokers (nD)
 †
 0.7 -0.3, 1.8 -0.2 -1.1, 0.6 -0.06 -1.2, 1.1 -0.2 -0.9, 0.6 
Current smokers (D)
 †
 -1.3 -2.4, -0.2* -1.0 -1.8, -0.02* -0.1 -1.9, 1.7 -0.7 -1.3, 0.3 
         
***p < 0.001; **p < 0.01; *p < 0.05.  
† 
nD = non-dependent; D = nicotine-dependent 
a 





We examined the severity and course of depressive and 
anxiety symptoms by smoking and nicotine dependence status in 
patients with current diagnosis of depression/anxiety disorders. Our 
results confirmed that the symptoms of depression, anxiety, and 
agoraphobia were more severe in nicotine-dependent smokers than in 
the other three groups. This pattern remained after controlling for the 
effects of covariates. The differences between the groups in the 
symptoms of social anxiety, however, were much smaller and were no 
longer significant after controlling for covariates. We also found that 
nicotine-dependent smokers had slower recovery of depressive and 
anxiety symptoms than never-smokers, former smokers, and non-
dependent smokers. However, no differences were observed between 
the groups for the improvement of the symptoms of social anxiety and 
agoraphobia. 
 
These results are in line with previous literature on the rates 
and severity of depression and anxiety disorders in nicotine-dependent 
smokers. After controlling for other substance disorders, nicotine-
dependent smokers (unlike non-dependent smokers) had higher odds of 
major depression and anxiety disorders
22





  were associated with elevated rates of 
depression and anxiety disorders and higher severity of depressive 
symptoms. 
 
Inconsistent with our hypothesis and with previous findings, 
we found that never-smokers, non-dependent current smokers, and 
former smokers did not differ significantly from each other on baseline 
symptom severity of depression and anxiety. However, when we 
combined the current smoking groups, our results were not different 
from previous studies that observed less severe symptoms of 
depression and anxiety in former smokers than in current smokers
3, 11
. 
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The previous studies did not distinguish between dependent and non-
dependent smokers. Thus it seems that the association between 
smoking and severity of symptoms is mainly carried by nicotine-
dependent smokers. 
 
Our findings should be interpreted by taking into consideration 
the following limitations. Firstly, despite the longitudinal design and 
the large sample size, the follow-up period is relatively short.  
Secondly, the age-group of the participants is heterogeneous. Thirdly, a 
number of participants had dropped out during the follow-up period 
which might have biased our results because the drop-outs were 
significantly different from those in the study in a number of 
parameters including severity of symptoms. Fourthly, nicotine 
dependence was assessed only at baseline, and was not assessed in 
former smokers. Fifthly, though our findings are suggestive of an 
association of slower symptom recovery with nicotine dependence, 
these cannot be taken as inferring causality due to the naturalistic 
nature of the study. Sixthly, NESDA may not be representative of other 
ethnic groups. Finally, depression and anxiety disorders are highly 
comorbid with other mental health problems, so the exclusion criteria 
of NESDA may limit the generalizability of our findings
82
. However, 
as compared to NESDA, another large study of early-onset depression, 
GENRED, adopted a more stringent exclusion criteria
83
. Despite these 
limitations, our study focuses on psychiatric patients whereas most 
previous longitudinal studies used population samples. The NESDA’s 
assessment of depression and anxiety disorders is based on DSM-IV 
criteria unlike most previous studies that assessed symptoms, not 
diagnoses, and relied mostly on self-report measures of depressive and 
anxiety symptoms. Moreover, anxiety disorders and nicotine 
dependence have received relatively little research attention; most 
studies have investigated the smoking status-depression association. 
Thus our findings of low improvement rate in anxiety and depressive 
symptoms in nicotine-dependent smokers are of particular importance 
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because nicotine-dependent smokers seem to have reduced mental 
health than non-dependent smokers. 
 
The mechanisms underlying the association of smoking or 
nicotine dependence with depression and anxiety disorders are unclear. 
Our findings suggest that quitting smoking may not always be 
associated with reductions of depressive and anxiety symptoms, 
because the former smokers in our study were not significantly 
different from non-dependent current smokers. However, there is no 
assessment of how severe the symptoms of former smokers were prior 
to quitting smoking.  Further, there is no information on how dependent 
the former smokers were when they quit.  It may be that it is dependent 
smoking that exacerbates symptoms among this population, but that if 
these smokers quit they would notice symptom improvement. Thus, the 
findings are inconsistent with the assumption that quitting smoking is 
linked with aggravation in depressive or anxious symptoms
84, 85
. 
Quitting might be related with high symptoms in smokers with lower 
quitting self-efficacy
17
 or with failed quit attempts
86
, but not in those 
who remain abstinent for long period
87
. This cannot be implied, though, 
from our findings as there are no data on quitting self-efficacy or failed 
quit attempts in NESDA. The former smokers in our study remained 
abstinent at an average of approximately twelve years (data not shown) 
which might be the reason that their symptoms were comparable with 
never-smokers. However, it is still interesting that non-dependent 
smokers are not significantly different in their symptoms from the non-
smoking groups. Thus our findings suggest that smoking might be 
associated with the onset or the increasing severity of anxiety disorders 
only when smokers are nicotine-dependent. 
 
The worse outcome observed in nicotine-dependent smokers 
might be due to the fact that chronic nicotine use might have an adverse 
effect on the brain and the neurotransmission systems. For example, 
nicotine use and anxiety or depression have both been linked to 
elevated dopamine
88, 89
, low brain-derived neurotrophic factor (BDNF) 





, and low Monoamine Oxidase (MAO) activity
92, 93
. Future 
investigations are needed on the impact of smoking or nicotine 
dependence on the dopamine, BDNF levels and MAO activity in 
relation to anxiety or aversive mood states in order to elucidate the 
mechanisms, and to help better our understanding of the complex 
association.  
 
Regarding the notion of self-medication as motivator for 
smoking, our findings suggest that chronic and heavy nicotine use does 
not help to alleviate negative affect and may be even 
counterproductive. This may be used in educational programs for 
smokers who think that smoking helps them to control their mood 
states. Our findings also point to the importance of considering nicotine 
dependence symptoms in psychiatric patients in health prevention and 
intervention programs; thus more effective methods for managing 
depression and anxiety disorders should be developed. In psychiatric 
patients who smoke, a screening for nicotine dependence symptoms in 
medical settings would be useful to be implemented, and nicotine-
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Background. Smoking, especially nicotine dependence is associated with more 
severe symptoms of depression and anxiety disorders. However, the mechanisms 
underlying this association are unclear. We investigated the effect of BDNF 
Val
66
Met polymorphism on the severity of depressive and anxiety symptoms in 
never-smokers, former smokers, and current smokers with and without nicotine 
dependence. 
 
Methods. Participants from the Netherlands Study of Depression and Anxiety 
(NESDA) with a current diagnosis of depression and/or an anxiety disorder and 
with available BDNF Val
66
Met polymorphism data were included (N=1,271). 
Dependent variables were severity of symptoms and independent variables were 
smoking status and BDNF genotype. Age, sex, education, recent negative life events, 




Val carriers, nicotine-dependent smokers had more severe 
symptoms of depression and anxiety than non-dependent smokers, former smokers 
and never-smokers, whereas the latter three groups did not differ on severity of 
symptoms. In Met
66
 carriers, there were no differences among the four smoking 
groups on severity of depression and anxiety. Nicotine dependence was the strongest 




Conclusions. In patients with an affective disorder, the relationship between 
nicotine dependence and symptom severity may be moderated by the BDNF 
Val
66
Met polymorphism. These results may suggest that inherent genetic differences 
may be crucial for the worse behavioral outcome of nicotine, and that Val
66
Val 
carriers may benefit most in mental health from smoking cessation. 





Epidemiological and clinical research has provided substantial evidence 
of an association of smoking with depression and anxiety disorders
1-5
. Nicotine-
dependent smokers have relatively high rates and more severe symptoms of 
depression and/ or anxiety as compared to non-dependent smokers, former- and 
never-smokers
6-13
. Twin studies have indicated that the association between 
smoking / nicotine dependence and depression/ anxiety can be explained by 
genetic
14-18
, and / or environmental factors
14, 18-20
. However, the biological 
mechanisms underlying this association are not yet clear. 
 
Brain-derived neurotrophic factor, (BDNF), an important regulatory 
protein and densely-expressed neurotrophin in the central and the peripheral 
nervous system, is a member of the nerve growth factor family
21, 22
. It supports 
the survival, differentiation, and maintenance of neurons in the nervous 
system
23





and is involved in neuroplasticity mechanisms such as long-term potentiation 
that underlies learning and memory
26-28
. The BDNF protein is encoded by the 
BDNF gene which, in humans, is located on chromosome 11
29
. The single 
nucleotide polymorphism (SNP) rs6265 in BDNF gene results in an amino acid 








Met polymorphism in the brain-derived neurotrophic factor 
(BDNF) gene may be a plausible candidate gene polymorphism underlying 
smoking-depression/ anxiety association. An association of this polymorphism 
has been found with affective disorders, and to some extent, also with smoking 
and other addictive behaviors. For example, previous research points to the 
involvement of variation in BDNF Val
66
Met polymorphism in the 
pathophysiology of depression and anxiety disorders. Studies using magnetic 
resonance imaging found that Met
66
 allele carriers with depression had smaller 




. Smaller hippocampal volume is 
also a general characteristic of major depression
32
. A meta-analysis showed that 
the polymorphism was associated with major depressive disorder (MDD) only in 
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men, and that the MDD cases more often carried the Met
66
 allele and were often 




. However, findings from two 
cohorts and a meta-analysis indicated that Val
66
Met polymorphism is unlikely to 
play a role in the genetic susceptibility to depression in a large sample
34
. One 
possible reason of this lack of association might be the non-clinical nature of the 
sample and self-report assessment of depression
34
. Few studies investigated the 
relationship of combination of gene markers including BDNF Val
66
Met 
polymorphism with depression. Though single-loci analyses did not show 
evidence of a significant positive association of the polymorphism with major 
depression, haplotype analysis of the combination of markers including BDNF 
rs6265
35-37
 produced significant associations with major depression. A recent 
mega-analysis of genome-wide association studies, however, failed to reveal an 




No association of BDNF Val
66
Met polymorphism has been found with 





and post-traumatic stress disorder
43





Few studies examined the relevance of this polymorphism with 
addictive behaviors. For example, heroin-dependent Met
66
 carriers were more 





. In another study it was found that Met
66
 carriers drank more 
alcohol per week, were more anxious to tolerate pressure and stress, and showed 




. A recent 
study found that variation in BDNF Val
66
Met polymorphism might be involved 
in smoking in schizophrenic patients
47
. In a healthy adult German sample (N = 
320), the frequency of the Met
66
 allele of BDNF gene was higher in current and 
former smokers than in never-smokers
48
. However, another study failed to 
replicate these findings
49
. In a recent study with healthy Chinese male 
population (322 smokers, 306 non-smokers), age at the onset of smoking was 
associated with BDNF Val
66
Met polymorphism such that smokers with the 
Met
66
 allele initiated smoking significantly earlier than the Val
66
Val 







 variant of the BDNF gene seems to be 
involved in addictive behaviors. 
 
In summary, although several studies supported the association of 
BDNF Val
66
Met polymorphism with clinical major depressive disorder, a large 
mega-analysis failed to identify a role of this polymorphism in depression. There 
is also some evidence of an association of the Met
66
 allele with smoking, 
although the number of studies and the sample sizes are limited. Smoking does 
appear to affect symptom severity in depression and anxiety disorders. It has 
been argued that psychiatric disorders may only be understood if both genetic 
and environmental factors are taken into account in the statistical models
38
, and 
that, in order to elucidate the underlying molecular mechanisms that may 
explain the association between phenotypes, gene-by-environment interaction 




In the present study, we investigated the interaction between the BDNF 
gene Val
66
Met polymorphism and smoking status on depressive and anxiety 
symptoms in a clinical sample. In a previous report, we found that nicotine-
dependent smokers had more severe symptoms of depression and anxiety 
disorders than non-dependent smokers, former smokers, and never-smokers
52
. 
The current study investigated a possible involvement of the BDNF gene 
Val
66




Participants and Data 
 
Participants were selected from the Netherlands Study of Depression 
and Anxiety (NESDA), an on-going naturalistic prospective cohort study. 
NESDA started in September 2004 and investigates the long-term course and 
consequences of depression and anxiety disorders by examining clinical, 
psychosocial, biological and genetic determinants. At baseline, NESDA 
consisted of 2,981 participants (66.4 % females) between 18 to 65 years of age. 
Participants were recruited from mental health care, primary care, and the 
general population in order to represent the entire range of psychopathology. 
The sample consisted of persons with a current diagnosis of anxiety and/or 
depression (57 %), persons with a remitted history of the disorders (21 %) and 
healthy controls (22 %). The two exclusion criteria were (i) a primary diagnosis 
of a psychotic disorder, addiction disorder, obsessive-compulsive disorder, or 
bipolar disorder and (ii) not being fluent in Dutch. Data were collected on 
demographic, clinical, psychosocial, psychological, and physiological variables, 
and health behaviors including alcohol intake, smoking, drug use, and physical 
activity. For data collection, self-report questionnaires, interviews, a medical 
examination, a cognitive computer task, and blood and saliva samples were 
gathered. NESDA protocol was approved by the Ethical Review Board of the 
VU University Medical Center and the local review boards of participating 
centers. All participants provided written informed consent. Further details on 





In the present study, we selected participants who had a current (past 6 
months) diagnosis of depression and/or an anxiety disorder at the baseline 
assessment and for whom information on BDNF genotype was available (N= 
1,271). 
 







Smoking behavior was measured by a questionnaire that covered past 
and current smoking behavior. Participants were classified into four groups 
based on their smoking status: never-smokers, former smokers, non-dependent 
smokers and nicotine-dependent smokers. Former smokers were those who 
stopped smoking definitively, and never-smokers were those who had no 
lifetime history of smoking. Nicotine dependence was assessed with the 
Fagerstrom Test for Nicotine Dependence (FTND)
54
. The reliability and internal 
consistency of FTND have been shown in previous research
55
. The FTND (score 
range: 0-10) assesses daily smoking rate, the interval between waking up and 
smoking the first cigarette, frequency of smoking after waking up, difficulty 
refraining from smoking in places where it is forbidden, and despite medical 
illness, and difficulty giving up the first cigarette in the morning. Current 
smokers with a score of 4 or higher on the FTND in the present study were 






 The Composite International Diagnostic Interview (CIDI version 2.1)
57
 
was used to assess the DSM-IV criteria for anxiety and depressive disorders. 
The CIDI has high inter-rater reliability, high test-retest reliability and high 




 Severity of depressive symptoms was assessed by the Inventory of 
Depressive Symptomatology (IDS). The IDS (score range: 0–84) is a 30-item 
self-report inventory which has shown high correlations with observer rated 
scales
58
. The 21-item Beck Anxiety Inventory (BAI; score range: 0-62) was used 
to assess severity of anxiety symptoms
59
. The symptoms of fear were measured 
with the 15-item Fear Questionnaire
60
. We used two sub-scales of the Fear 
Questionnaire: (i) FQ items for social fear symptoms, and (ii) FQ items for 
agoraphobia symptoms
60
. The sum score of both sub-scales ranges from 0 to 40. 








The Alcohol Use Disorder Identification Test (AUDIT) was used to 
assess alcohol intake
62
. The International Physical Activity Questionnaire 
(IPAQ) was used to measure physical activity. IPAQ estimates weekly energy 
expenditure based on daily physical activities
63
. Negative life events in the past 
year were assessed with the List of Threatening Events Questionnaire (LTE-
Q)
64
. These events reflect the occurrence of stressful events such as serious 
personal illness or injury, death or loss of a loved one, and financial problems in 
the past year. Body mass index (BMI) was calculated (kg/m
2
). Other covariates 
under study were age, sex, and education. These covariates were chosen because 






 Venous blood samples were collected at baseline (between 0830 and 
0930 hours) after overnight fasting and DNA was isolated using the FlexiGene 
DNA AGF3000 kit (Qiagen, Valencia, CA, USA) on an AutoGenFlex 3000 
workstation (Autogen, Holliston, MA, USA). DNA concentrations were 
determined using the PicoGreens dsDNA Quantitation kit from Molecular 
Probes. Genotyping of the participants was conducted by Perlegen Sciences 
(Mountain View, CA, USA) using four proprietary, high-density oligonucleotide 
arrays. Detailed description of how genotyping was performed has been 
published elsewhere
71
. To extract the Val
66
Met polymorphism from the whole 
genome data, PLINK software version 1.07 
(http://pngu.mgh.harvard.edu/~purcell/plink/) was used. The imputation 
accuracy of rs6265 (Val
66
Met polymorphism) was 99.9 % (r2hat = 0.999).  
 
 The current sample consists of 65.8 % Val
66
Val and 3.5 % Met
66
Met 
homozygotes, whereas 30.7 % were Val
66
















Preliminary analyses were conducted to ensure no violation of the 
assumptions of univariate and multivariate analysis. Normality of distributions, 
linearity, and multicollinearity, heterogeneity of variance, outlying scores, and 
coding errors were checked. The Hardy-Weinberg equilibrium for the BDNF 
polymorphism was tested using a chi-square test for goodness of fit. Differences 
on demographic and clinical characteristics between the groups stratified 
according to their smoking status were determined with one-way between-
groups ANOVA and chi-square test for independence. The association of BDNF 
Val
66
Met polymorphism was examined, separately, with smoking status, 
nicotine dependence, and with the symptoms of depression and anxiety 
disorders, using chi-square test for independence, independent-samples t-test, 
and multivariate ANCOVA, respectively. Next, the estimates of the interaction 
effects of genotype and smoking status on the symptoms of depression and 
anxiety disorders were computed with multivariate ANCOVA while controlling 
for the covariates on which the groups differed significantly. In order to control 
for the potentially confounding influences of the covariates on the main and the 
interaction effects of the BDNF genotype and smoking status, we entered all the 
covariate x smoking status and the covariate x BDNF gene interaction terms in 
the same model that tests the BDNF gene x smoking status interaction term, 
along with the simple effects of the covariates
72, 73
. Significant interaction 





 carriers. Eta squared and partial eta squared were used as the 
measures of effect size, and alpha level of 0.05 was used. Finally, the predictors 





using multiple linear regression analyses. Two models were fitted in each 
regression analysis. In the first model, we entered age, sex, education, past year 
negative life events, alcohol intake and body mass index, and in the second 
model we added nicotine dependence. Thus the estimates provided from the 






Preliminary analyses did not indicate any serious violation of the 
assumptions of univariate and multivariate tests. The genotype distributions in 
the four smoking groups did not deviate significantly from the Hardy-Weinberg 
Equilibrium (never-smokers: p = 0.5; former smokers: p = 0.6; non-dependent 
smokers: p = 0.3; nicotine-dependent smokers: p = 0.7). 
Sample Characteristics 
 
Of the 1,271 participants, 24.6 % were never-smokers, 31.0 % were 
former smokers, and 44.4 % were current smokers. Of the current smokers, 46.5 
% were nicotine-dependent. The smoking groups differed significantly with 
respect to age (F (3, 1267) = 26.1; p < 0.001), education (F (3, 1267) = 12.1; p < 
0.001), past year negative life events (F (3, 1267) = 6.6; p < 0.001), alcohol intake 
(F (3, 1252) = 33.8; p < 0.001), and body mass index (F (3, 1266) = 5.0; p < 0.01). No 
group differences were found in physical activity, sex distribution, and BDNF 
genotype (ps  > 0.05). Post-hoc comparisons between the smoking groups for 
significant association of continuous variables are presented in table 1. 
Association of BDNF Genotype with Smoking, and with 
Symptom Severity 
 
No association of smoking status with BDNF genotype was found. The 
four smoking groups did not differ significantly in allele distribution (p > 0.05). 
We also examined allele distribution by collapsing the four smoking groups into 
two groups of current smokers (non-dependent and dependent) and non-smokers 
(former and never-smokers), however, the difference did not reach significance 
(p > 0.05). 
 
Multivariate ANCOVA revealed that the main effect of BDNF 
Val
66
Met polymorphism on the severity of symptoms of depression, general 
anxiety, social anxiety and agoraphobia was non-significant (ps > 0.05). 
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N = 313 
Former 
smokers 
N = 394 










N = 302 
Nicotine-
dependent 
N = 262 
           
Age (Mean, SD) 38.7 12.8 45.3 11.8 38.4 11.9 41.7 10.7 0.06*** FS>D>FS,NS 
Sex, F (N, %) 220 70.3 262 66.5 208 68.9 164 62.6 ns  
Education, in years (Mean, SD) 12.2 3.2 12.1 3.3 11.8 3.1 10.7 3.1 0.03*** D<nD,FS,NS 
Past year negative life events 
(Mean, SD) 
0.9 1.1 0.9 1.0 1.0 1.2 1.3 1.4 0.02*** D>nD,FS,NS 
Alcohol use (Mean, SD) 2.9 3.4 4.8 4.6 6.5 5.5 6.5 6.7 0.07*** nD,D>FS>NS 
Physical activity (Mean, SD)
1
 3.4 2.9 3.6 3.0 3.9 3.5 3.6 3.6 ns  
Body mass index (Mean, SD) 25.6 5.2 26.4 5.1 24.8 4.8 25.5 5.6 0.01** nD<FS 
           
BDNF genotype (N, %)         ns  
           
Val
66
Val carriers 211 67.4 268 68.0 183 60.6 174 66.4   
Met
66 
carriers 102 32.6 126 32.0 119 39.4 88 33.6   
***p < 0.001, **p < 0.01, *p < 0.05
 
1









Interaction Effect of BDNF Genotype and Smoking Status on 
Symptom Severity 
 
A multivariate ANCOVA showed that the BDNF genotype and 
smoking status interaction effect was significant for symptoms of depression (F 
(3, 1230) = 3.1; p < 0 .05; partial η2 = 0.01) and anxiety (F (3, 1230) = 2.8; p < 0.05; 
partial η2 = 0.01), while non-significant for symptoms of social anxiety and 
agoraphobia (ps > 0.05). 
 
The subsequent univariate ANCOVAs revealed that in Val
66
Val 
carriers, the main effect of smoking status on symptoms of depression (F (3, 812) = 
8.7; p < 0.001; partial η2 = 0.03) and general anxiety (F (3, 813) = 5.6; p = 0.001; 
partial η2 = 0.02) was significant. Pairwise comparisons showed that nicotine-
dependent smokers had significantly more severe symptoms of depression and 
general anxiety than non-dependent smokers, former smokers, and never-
smokers (ps < 0.05). Never-smokers, former smokers, and non-dependent 
current smokers did not differ significantly from each other (ps > 0.05) on 




 carriers, the main effect of smoking status on severity of 
symptoms of depression and general anxiety was non-significant in the 
univariate ANCOVA (ps > 0.1), suggesting that smoking groups carrying Met
66
 
allele did not differ significantly from each other on severity of symptoms of 
depression and general anxiety (table 2). 
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Table 2. Estimates of the severity of symptoms of depression and anxiety disorder in different smoking groups stratified 
according to their BDNF genotype
a
 
      
Severity of 
symptoms 









             







23.1 4.2 14.9, 
31.3 
26.0 1.3 23.4, 
28.7 
33.1 2.1 29.0, 
37.2 
43.8 4.9 34.2, 
53.4 
.03*** 
              
Symptoms of 
anxiety 
11.3 3.6 4.2, 
18.3 
14.2 1.1 11.9, 
16.4 
18.9 1.8 15.4, 
22.4 









25.7 5.4 15.0, 
36.3 
28.1 2.0 24.1, 
32.0 
30.2 2.4 25.5, 
34.9 
32.9 6.1 21.0, 
44.9 
ns 
              
Symptoms of 
anxiety 
13.3 4.6 4.3, 
22.4 
15.4 1.7 12.0, 
18.7 
17.5 2.0 13.6, 
21.5 
18.1 5.1 8.0, 
28.3 
ns 




Adjusted for covariates and their interactions with smoking and genotype. 
b






Predictors of Symptom Severity 
 
Regression analyses indicated that in the Val
66
Val group, the first model 
with age, sex, education, negative life events, alcohol intake, and body mass 
index explained 7.6 % of the variance in severity of depression (p < 0.001). The 
second model that added nicotine dependence accounted for an additional 5 % 
of the significant variance (R
2
 = 0.125; p < 0.001). In Met
66
 carriers, only the 
first model with age, sex, education, negative life events, alcohol intake, and 
body mass index explained significant variance (R
2
 =0.07, p < 0.05). 
 
The same pattern emerged with anxiety severity as the dependent 
measure. In the Val
66
Val group, the first model explained 6.4 % variance in 
severity of anxiety (p = 0.001), and the second model with nicotine dependence 
accounted for an additional 5 % of the significant variance (R
2
 =0.12; p < 
0.001). In Met
66
 carriers, only the first model explained significant variance (R
2
 
=0.10; p < 0.01).  
 
Nicotine dependence was the strongest significant predictor of the 
symptoms of depression and anxiety only in Val66Val carriers (table 3). 
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Table 3. Regression of nicotine dependence on the severity of symptoms stratified according to the BDNF genotype 
   
 BDNF Val
66
Val carriers BDNF Met
66
 carriers* 
   
Predictors B SE Β p B SE β p 
         
 Severity of depression 
Age -0.07 0.06 -.07 ns 0.01 0.07 .01 ns 
Sex 0.78 1.39 .03 ns -0.03 1.82 .001 ns 
Education -0.49 0.21 -.13 * -0.67 0.27 -.18 * 
Negative life events 0.55 0.51 .06 ns 0.06 0.77 .01 ns 
Alcohol intake 0.01 0.12 .004 ns -0.04 0.17 -.02 ns 
BMI 0.38 0.13 .16 ** 0.31 0.17 0.13 ns 
Nicotine dependence 1.11 0.26 .24 *** 0.58 0.34 .12 ns 
 Severity of general anxiety 
Age -0.05 0.05 -.05 ns -0.01 0.06 -.01 ns 
Sex -0.10 1.18 -.004 ns -1.40 1.56 -.06 ns 
Education -0.45 0.17 -.14 * -0.90 0.23 -.27 *** 
Negative life events 0.53 0.44 .06 ns -0.26 0.67 -.03 ns 
Alcohol intake 0.07 0.10 .04 ns 0.05 0.14 .02 ns 
BMI 0.20 0.11 .10 ns 0.21 0.14 .11 ns 
Nicotine dependence 0.96 0.22 .24 *** 0.41 0.29 .10 ns 







We previously reported that nicotine-dependent smokers had more 
severe symptoms of depression and anxiety disorders than non-dependent 
smokers, former smokers, and never-smokers
52
. In the present study, we 
examined the role of the BDNF Val
66
Met polymorphism in this association.  
 
The BDNF polymorphism had no direct effect on smoking status and 
on the severity of affective symptoms in the present sample. However, we did 
observe an interaction of smoking status and BDNF polymorphism with the 
symptoms of depression and anxiety. In Val
66
Val carriers, nicotine-dependent 
smokers had more severe symptoms of depression and anxiety disorder than 
non-dependent smokers, former smokers and never-smokers, whereas the latter 
three groups were comparable in symptom severity. In Met
66
 carriers no 
differences among the four smoking groups were found in symptoms of 
depression and anxiety. We also found that after controlling for the potential 
confounding variables, nicotine dependence was the strongest predictor of the 
symptoms of depression and anxiety only in Val
66
Val homozygotes. These 
findings suggest that genetic predisposition and nicotine dependence may act 
interdependently in the severity of symptoms of affective disorders. 
 
These findings need to be replicated as there is no previous report on 
the interacting effects of BDNF gene and smoking status on depressive and 
anxiety symptoms. Most of the previous literature is based on association studies 
that look for a direct relationship of BDNF Val
66
Met polymorphism with 
depression, or with smoking, and most of the studies examined genotype or 
allele frequencies. In order to elucidate the underlying molecular mechanisms 
through which variation in the BDNF gene may lead to severity of symptoms, 
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The observed association might be interpreted in the context of previous 
MRI research which shows that Val
66
Val genotype is associated with reduced 
hippocampal gray matter volumes  in healthy Caucasian participants
74
. Further, 
reduced hippocampal gray matter volume has also been associated with major 
depression
32
. Thus, nicotine-dependent smokers who carry Val
66
Val variant of 
the BDNF gene may have reduced hippocampal gray matter volume and thus 
may experience more severe symptoms than Met
66
 carriers whose brain 
morphology may not be depression-vulnerable. This speculation has been 
supported by animal research. In a recent animal model of depression, nicotine 
administration exacerbated depressive-like behavior in inbred Wistar-Kyoto 
(WKY) rats, which had reduced hippocampal volume but not in the control 
Wistar rats with comparatively large hippocampal volume
75
. Research has also 
shown greater genotypic variability among WKY rats compared to other inbred 
strains
76, 77
. It has been proposed that the differential responses of WKY and 
Wistar rats to nicotine may reflect genetic differences
75
. Thus, the current 
findings suggest that genetic differences are important determinants to explain 
worse behavioral outcome of nicotine in some individuals but not in others. 
However, this theory needs to be confirmed in future MRI and genetic 
investigations. 
 
This study has some limitations which should be taken into account. 
Firstly, we investigated only one polymorphism, therefore it is likely that other 
polymorphisms in the BDNF gene or other genes are involved. Secondly, the 
study is cross-sectional and causality cannot be inferred. Thirdly, our findings 




A strength of our study is the relatively large sample size compared to 
prior research in this area. We investigated patients with a diagnosed psychiatric 
disorder, unlike most previous studies that used samples from general 
population. The depression and anxiety disorder diagnoses were made according 
to DSM-IV criteria, whereas most previous studies assessed symptoms using 
self-report measures. The study sample is ethnically homogenous and we were 
able to control for a large number of covariates. 
 
Despite a well-established association between smoking and depression 
and anxiety disorders, the mechanisms underlying this association have rarely 
been investigated from a genetic perspective. Only few studies have investigated 
the interacting effects of genetic predisposition and depressive symptoms on 
smoking. The two short alleles of DRD4 gene are associated with self-
medicating smoking practices in depressed individuals
78
. Similarly, smokers 
with severe depressive symptoms were progressing to a higher level of smoking 
only if they had DRD2A1 allele
79
. However, these studies support the notion of 
smoking as a self-medicating agent to alleviate depressive symptoms. The 
theory, that smoking is a vulnerability factor in depression and anxiety has 
recently been investigated using the rs1051730 SNP variant located in the 
nicotine acetylcholine receptor gene cluster on chromosome 15. Self-reported 
smoking was positively associated with the prevalence of both anxiety and 
depression, and the measured polymorphism was positively associated with 
smoking. However, no association of the polymorphism with either anxiety or 
depression was found among smokers suggesting that smoking is not a causal 
factor of anxiety and depression
80
. Our results, however, are supportive of the 
‘smoking as a vulnerability factor in depression/ anxiety’ theory. We found a 
genotype-dependent dose-response relationship between nicotine dependence 
and symptom severity. Though, this theory could not be elucidated in the current 
study because of its cross-sectional nature, it may provide a starting point for 
understanding the neurobiological links between smoking or nicotine 
dependence and affective disorders. 
 
This study has clinical implications, for example, Val
66
Val carriers may 
benefit most from smoking cessation or lowering amount of smoking. It could 
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still be that smoking in this group is a failed attempt at self-medication. Thus, 
future study could focus on immediate versus longer-term subjective effects of 
lighting a cigarette in this group. If it turns out that smoking reduces anxiety in 
the short-term, this group may particularly benefit from other interventions that 
reduce anxiety while they attempt to quit. 
 
This study, also, has important implications for future molecular 
research on smoking-psychopathology association. Given the high prevalence of 
depression and anxiety in smokers, it is important to focus on investigating the 
genetic and biological influences to elucidate the mechanisms underlying the 
association between smoking and affective disorders. Similarly, ethnicity should 
be given consideration because of the ethnic differences in genotype and allele 
frequencies
42
. Moreover, DSM assessment for nicotine dependence may be 
more useful for identifying smokers vulnerable to depression and anxiety
81
. 
Understanding of genetic influences on smoking-psychopathology association 
may be significant for guiding smoking prevention and intervention programs in 
identifying smokers, particularly those with nicotine dependence who are 
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Background. Nicotine use is associated with up-regulation of brain-derived 
neurotrophic factor (BDNF) in serum. An association of smoking with BDNF 
Val
66
Met polymorphism has also been found. The aim of the current study is to 
examine the levels of serum BDNF in never-smokers, former smokers and current 
smokers with and without nicotine dependence, and to examine the interaction of the 
polymorphism and smoking status with serum BDNF. 
 
Methods. We used baseline BDNF serum and gene data from the Netherlands Study 
of Depression and Anxiety (NESDA). The data were available for 2,088 
participants. Age, sex, education, alcohol use, physical activity, recent negative life 
events, body mass index, the use of anti-depressants, the diagnosis of an affective 
disorder, were treated as covariates. Nicotine dependence was assessed using the 
Fagerstrom test for nicotine dependence (FTND). 
 
Results. Smokers with and without nicotine dependence had higher levels of serum 
BDNF  than former and never-smokers. Nicotine dependence and number of 
cigarettes smoked per day did not further add  to the  prediction of serum BDNF; 
however, total number of smoking years was a significant predictor of serum BDNF. 
There was no interaction of BDNF genotype and smoking status with serum BDNF. 
 
Conclusions. Current smoking and higher number of smoking years are associated 
with higher levels of serum BDNF, independent of BDNF genotype. Nicotine 
dependence itself is not associated with further increase or decrease of serum 
BDNF. 
 




Brain-derived neurotrophic factor (BDNF), a small dimeric protein, is a 
member of the neurotrophin family of growth factors
1
. It is densely expressed in 
the central and the peripheral nervous system, and is the most abundant of the 
neurotrophins in the brain with high concentrations in the hippocampus and 
cerebral cortex
2, 3
. It is involved in the growth, development, regeneration, 
survival, maintenance and function of neurons
4
. It is also involved in the 
modulation of neurotransmitter release across several neurotransmitter systems 




, and glutamatergic 
neurotransmitter systems
7-9
, and in the plasticity mechanisms such as long-term 
potentiation
10
, a cellular mechanism underlying learning and memory. 
 
Peripheral BDNF is highly concentrated in platelets
11-13
, with 
approximately 50 to 200 fold higher circulation in serum than in plasma
14, 15
. 
The difference between the levels of serum and plasma BDNF could reflect the 
release of BDNF from platelets during blood clotting
11
. In animals, the brain and 
peripheral BDNF levels undergo similar changes during growth and 
developmental process, and BDNF levels in serum correlate positively to 
cortical BDNF
16
, indicating that peripheral BDNF levels may be reflective of 
BDNF levels in the brain. 
 
The BDNF protein is encoded by the BDNF gene which, in humans, is 
located on chromosome 11
17
. The single nucleotide polymorphism (SNP) rs6265 







As already mentioned, BDNF expression in the brain is regulated by the 
serotonergic
5
 and the dopaminergic
19
 neurotransmitter systems which are known 
to be involved in nicotine use and addictive behaviors
20-24
. For instance, studies 
have indicated that nicotine exposure increases brain serotonin secretion
25
, that 
the serotonin transporter genes is associated with smoking behavior
26-29
 and that 
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Evidence from animal studies indicates that high levels of brain BDNF 
may be associated with drug addiction. Nicotine infusion in neonatal piglets 
significantly increases the expression of BDNF mRNA and protein in the 
hippocampus
30
, and hippocampal BDNF mRNA expression is enhanced or 




Given the difficulty of the direct examination of brain BDNF in 
humans, the levels of BDNF have been primarily studied in the periphery, 
mainly in the blood serum. In a Chinese sample of chronic schizophrenic 
inpatients (N=139; 102 smokers) with no drug or alcohol dependence, smokers 
had higher levels of serum BDNF than non-smokers. The number of cigarettes 
smoked per day was positively correlated with serum BDNF levels
32
. In a small 
subsample of the current study that has investigated the determinants of serum 
BDNF in individuals with no current diagnoses of major depression or anxiety 
disorder, a positive association of serum BDNF and smoking was found, 
suggesting that smoking is associated with increasing serum BDNF levels
33
. In 
summary, these findings suggest that the effect of nicotine use on central and 
peripheral BDNF expression depends on the amount of smoking. Higher number 
of cigarettes smoked per day and chronic nicotine exposure might be associated 
with up-regulation of serum BDNF levels. 
 





, with the frequency of the Met allele of the 





The aim of the present study was to investigate the effect of smoking 
severity and chronicity on serum BDNF levels, and to examine the effect of 
BDNF Val
66
Met polymorphism in this association. We hypothesized that (i) 
both groups of current smokers, that is, non-dependent and nicotine-dependent 
smokers would have higher levels of serum BDNF than the non-smoking groups 
 
                                                                     Smoking and Serum BDNF 
 111 
of former- and never-smokers; (ii) nicotine-dependent smokers would have 
higher serum BDNF than non-dependent smokers; (iii) former and never-
smokers would be comparable in serum BDNF levels; (iv) number of cigarettes 
smoked per day, total smoking years, and nicotine dependence would be 
positively correlated with serum BDNF. We will adjust the analyses for several 
potential confounding variables, including the presence of depressive and 
anxiety disorders, which have been shown to be associated with BNDF
36-39
 as 
well as with smoking behavior
40-43
. Further, we will also examine the interaction 
of smoking status and BDNF Val
66




Participants and Data 
 
Participants were selected from the Netherlands Study of Depression 
and Anxiety (NESDA), an on-going prospective cohort study which started in 
September 2004. Recruitment took place in mental health care organizations, 
primary care, and in the general population. The baseline NESDA sample 
consists of 2,981 participants (66.4 % females) between 18 to 65 years of age, 
with a current diagnosis of anxiety and / or depression (57 %), with a history of 
these disorders (21 %) and with no lifetime history of these disorders (22 %). 
Exclusion criteria were primary diagnosis of a psychotic disorder, addiction 
disorder, obsessive-compulsive disorder, or bipolar disorder. Approval of the 
NESDA protocol was obtained from the Ethical Review Board of the VU 
University Medical Center and from the local review boards of participating 
centers. All participants signed informed consent for the study after full 
information about the study was provided to them.  Further details on the 




In the present study we selected participants for whom data on serum 
BDNF and BDNF gene Val
66
Met polymorphism were available (N= 2,088). The 
sample was stratified into never-smokers, former smokers and current smokers 





Smoking behavior was assessed by a questionnaire. The Fagerstrom test 
for nicotine dependence (FTND) was used to assess nicotine dependence
45
. The 
reliability and internal consistency of FTND have been shown in previous 
research
46
. The FTND assesses daily smoking rate, the interval between waking 
up and the first cigarette, frequency of smoking after waking up, difficulty 
refraining from smoking in places where it is forbidden, and despite medical 
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illness, and also difficulty delaying the first cigarette in the morning. The sum 
score of the FTND ranges from 0-10. We grouped the participants into four 
smoking groups of never-smokers (those who had no lifetime history of 
smoking), former smokers (those who had stopped smoking definitively), non-
dependent smokers (those current smokers who had scored less than 4 on 
FTND) and nicotine-dependent smokers (those current smokers who had scored 




Potential confounding variables 
 
The current (6-month recency) diagnoses of major depression and 
anxiety disorders were ascertained using the Composite International Diagnostic 
Interview (CIDI version 2.1). The CIDI is a structured interview designed to 
assess diagnoses of psychiatric disorders according to DSM-IV criteria. The 
CIDI has high inter-rater reliability, high test-retest reliability and high validity 
for depressive and anxiety disorders
49
. The Alcohol Use Disorder Identification 
Test (AUDIT) was used to assess alcohol intake
50
. The International Physical 
Activity Questionnaire (IPAQ) was used to measure self-reported physical 
activity. IPAQ estimates weekly energy expenditure based on daily physical 
activities
51
. Body mass index (BMI) was calculated as weight in kilograms 
divided by height in meters squared (weight /height
2
). Past year negative life 
events were assessed with the Brugha questionnaire
52
. Data on the use of 
antidepressants were acquired through drug container observation and self-
report. Use of an antidepressant was defined as intake of minimally the daily 
dose as recommended by the World Health Organization during the last month 
on at least 50 % of the days. The duration of use was expressed in months
53
. All 
methods were standardized through periodical external quality assessments by 
the Dutch Foundation for Quality Assessment in Clinical Laboratories. Other 
covariates under study were age, sex, and education. These covariates were 






Blood (50ml) was drawn (between 0730 and 0930 hours) after an 
overnight fast, and serum was separated and stored at -85
o
C until it was assayed. 
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EmaxImmuno Assay system from Promega was used to measure BDNF protein 
levels according to the manufacturer’s protocol (Madison, WI, USA). In order to 
increase the detectable BDNF in a dilution-dependent way, the undiluted serum 
was treated with acid. Grenier Bio-One high affinity 96-well plates were used. 
Serum samples were diluted 100 times, and the absorbency was read in 
duplicate using a Bio-Rad Benchmark microplate reader at 450 nm.  Serum 
BDNF protein levels were expressed in nanograms per milliliter (ng/ml). The 
intra- and inter-assay coefficients of variation were found to be within 3 % and 9 
%, respectively. Prior to analyses, BDNF values that were three standard 
deviations (SD) above the mean (n=5, 0.35 %) were trimmed to a value of the 
mean plus three SDs. One BDNF value (0.07 %) was below the reliable 
detection limit of the ELISA kit of 1.56 ng/ml and was set at the lower detection 
limit of 1.56 ng/ml. Persons with missing and non-missing BDNF were not 




 Venous blood samples were collected at baseline (between 0830 and 
0930 hours) after overnight fasting and DNA was isolated using the FlexiGene 
DNA AGF3000 kit (Qiagen, Valencia, CA, USA) on an AutoGenFlex 3000 
workstation (Autogen, Holliston, MA, USA). DNA concentrations were 
determined using the PicoGreens dsDNA Quantitation kit from Molecular 
Probes. Genotyping of the participants was conducted by Perlegen Sciences 
(Mountain View, CA, USA) using four proprietary, high-density oligonucleotide 
arrays. Detailed description of how genotyping was performed has been 
published elsewhere
57
. To extract the Val
66
Met polymorphism from the whole 
genome data, PLINK software (http://pngu.mgh.harvard.edu/~purcell/plink/) 
was used. The imputation accuracy of rs6265 (Val
66
Met polymorphism) is  99.9 
% (r2hat = 0.999).  
  
 The current sample consists of 64.8 % Val
66
Val and 3.4 % Met
66
Met 
homozygotes, whereas 31.8 % were Val
66
Met heterozygotes. We combined the 
low-frequency homozygous Met
66
Met carriers with the heterozygous Val
66
Met 








Data were checked for outliers and coding errors. Preliminary analyses 
indicated no serious violation of the assumptions of univariate and regression 
analyses. Between-group differences on demographic, health, and clinical 
characteristics were determined using one-way ANOVAs (with post-hoc tests 
for significant F-statistic) and chi-square test for independence. The Hardy-
Weinberg equilibrium for the BDNF polymorphism was tested using a chi-
square test for goodness of fit. Estimates of the main and interaction effects of 
smoking status and BDNF Val
66
Met polymorphism on serum BDNF levels were 
determined using univariate ANCOVA. The model was adjusted for the 
potential confounding effects of the variables on which the groups differed. 
These covariates were age, education, alcohol use, BMI, number of negative life 
events in the past year, and the use of anti-depressants. Significant effects were 
further followed by similar ANCOVA, while adjusting for the above-mentioned 
covariates. Correlation of serum BDNF with number of cigarettes smoked per 
day, total smoking years, and nicotine dependence was conducted. Finally, 
multiple linear regression was run to see how much of the variance in serum 
BDNF is explained by smoking severity, which was assessed by number of 
cigarettes smoked per day and nicotine dependence and chronicity, as assessed 
by total years of smoking. The independent variables/ covariates were entered 
by fitting three models. In the first model, we entered age, sex, education, and 
past year negative life events. The second model added alcohol use, BMI, anti-
depressant use, and the presence of an affective disorder.  In the third model, we 
added number of cigarettes smoked per day, total smoking years, and nicotine 
dependence. Thus, the estimates provided from the final model included all 
variables. Analyses were run in PASW (V. 19.0) for windows. Statistical 
significance was set at p < 0.05. Eta squared, partial eta squared and Cramer’s V 






Of the 2,088 participants, 27.0 % were never-smokers, 33.0 % were 
former smokers, and 40.0 % were current smokers. Of the current smokers, 36.7 
% were nicotine-dependent. The genotype distributions in the four smoking 
groups did not deviate significantly from the Hardy-Weinberg Equilibrium 
(never-smokers: p = 0.7; former smokers: p = 0.4; non-dependent smokers: p = 
0.3; nicotine-dependent smokers: p = 0.7).Table 1 presents the demographic, 
health and clinical characteristics of the participants stratified according to their 
smoking status. ANOVA revealed significant group differences in age (F (3, 2084) 
=35.0), years of education (F (3,2084) = 19.3), BMI (F (3,2082) = 6.4), alcohol use (F 
(3, 2064) = 49.8), past year negative life events (F (3,2084) = 9.3) and the use of anti-
depressant (F (3,2084) = 2.7), while a non-significant group difference in physical 
activity (p > 0.05). Post-hoc comparisons between the smoking groups on these 
variables are presented in Table 1. Chi-square test indicated that groups differ 
significantly in sex distribution (χ
2 
(3, 2088) = 9.3) and psychiatric status (χ
2
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Table 1. Baseline demographic and health behavior characteristics of the participants stratified according to their smoking status 
    
Demographic, health, and 
clinical characteristics 
Smoking status Effect 
size2 
Tukey2 
 Never-smokers Former 
smokers 
Current smokers   





 N = 564 N = 690 N = 528 N = 306   
 Mean SD Mean SD Mean SD Mean SD   
           
Age at baseline 39.5 13.5 45.9 12.0 39.8 12.8 42.4 11.4 0.05*** FS>D>nD & NS 
Education (years) 12.6 3.2 12.5 3.3 11.8 3.2 11.1 3.2 0.03*** NS & FS> nD > D 
Alcohol intake 3.3 3.4 4.7 4.1 6.5 5.5 6.1 5.8 0.07*** NS < FS < nD & D 
Physical activity 3.7 3.0 3.7 3.0 4.0 3.5 3.6 3.5 ns  
BMI 25.3 4.9 26.2 4.9 25.0 5.1 25.8 5.1 0.01*** NS & nD < FS 
Past-year negative life events 0.8 1.0 0.8 1.0 1.0 1.2 1.1 1.2 0.01*** NS & FS < nD & D 
Serum BDNF 8.8 3.1 8.9 3.3 9.4 3.6 9.5 3.6 0.01** NS & FS < nD & D 
Use of anti-depressants 0.4 0.9 0.5 1.0 0.5 1.0 0.6 1.0 0.004* D > NS 
           
 N % N % N % N %   
Sex, F 402 71.3 458 66.4 339 64.2 191 62.4 0.07*  
Current diagnosis of an 
affective disorder 
306 54.3 386 55.9 341 64.6 208 68.0 0.11***  
***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05 
1Mean met-minutes (ratio of energy expenditure during activity to energy expenditure at rest) divided by 1000 





Association of Smoking and BDNF Genotype with Serum 
BDNF 
 
Univariate ANCOVA revealed that, after adjusting for covariates, the 
main effect of smoking status on serum BDNF was significant (F (3, 2052) = 7.5; p 
< 0.001; partial η
2 
= 0.01) suggesting that the four smoking groups were 
significantly different in serum BDNF levels. The main effect of BDNF 
genotype and its interaction effect with smoking status were non-significant (ps 
> 0.05). Follow-up analyses revealed that serum BDNF of the two non-smoking 
groups, that is, never-smokers (Mean = 8.8, SD = 3.1) and former smokers 
(Mean = 8.9, SD = 3.3) were significantly lower than the two current smoking 
groups: non-dependent smokers (Mean = 9.4, SD = 3.6) and nicotine-dependent 
smokers (Mean = 9.5, SD = 3.6). Never-smokers were not significantly different 
from former smokers in serum BDNF levels (p > 0.05). Similarly, both the 
current smoking groups were comparable in serum BDNF (p > 0.05). 
 
Table 2. Regression of smoking status on serum BDNF 
1
 
     
Predictors B SE β p 
     
Age 0.03 0.01 .11 0.01 
Sex 0.09 0.27 .01 0.74 
Education 0.01 0.04 .01 0.85 
Past year negative life events -0.13 0.11 -.04 0.25 
Alcohol use 0.004 0.03 .01 0.88 
BMI 0.01 0.03 .02 0.59 
Anti-depressant use 0.06 0.13 .02 0.62 
Diagnostic status of an affective disorder 0.04 0.26 .01 0.87 
Number of cigarettes smoked per day -0.01 0.02 -.02 0.68 
Total smoking years 0.02 0.01 .10 0.05 
Nicotine dependence -0.13 0.12 -.05 0.26 
***p ≤.001; **p ≤.01; *p ≤.05; ns=non-significant. 
1
 Data have been shown only for the final model including all variables 
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Pearson product-moment correlation showed a significant positive 
correlation of serum BDNF with total years of smoking (r = 0.14, N = 2088, p < 
0.001), while a non-significant correlation with number of cigarettes smoked per 
day and nicotine dependence (ps > 0.05). 
Predictors of Serum BDNF 
 
Regression analysis indicated that the first model with age, sex, 
education, and past year negative life events explained 2.7 % of the variance in 
serum BDNF (p < 0.001). The second model with alcohol use, BMI, anti-
depressant use, and the presence of an affective disorder, and the final model 
with total years of smoking, cigarettes smoked per day, and nicotine dependence 
did not explain additional significant variance in serum BDNF (ps > 0.05). Age 
and total smoking years were significant predictors of serum BDNF, however, 
cigarettes smoked per day and nicotine dependence did not further predict serum 








We examined the levels of serum BDNF in never-smokers, former 
smokers, and current smokers with and without nicotine dependence, while 
controlling for the potential confounding variables. As we expected, non-
dependent and nicotine-dependent current smokers had higher levels of serum 
BDNF than the two non-smoking groups of former and never-smokers who 
were comparable in their serum BDNF levels. Inconsistent with our hypothesis, 
the two current smoking groups with and without nicotine dependence did not 
differ in serum BDNF. Moreover, we did not find nicotine dependence and 
number of cigarettes smoked per day to be significant predictors of serum 
BDNF. Thus, smoking severity had no effect on the levels of serum BDNF. 
However, total smoking years was a significant predictor of serum BDNF, 
indicating an influence of smoking chronicity on serum BDNF. Further, we did 
not find an interaction of BDNF genotype and smoking status on serum BDNF, 
which suggests that BDNF Val
66
Met polymorphism did not explain smoking-
serum BDNF association. 
 
Animal research has shown that BDNF mRNA and protein expression 
in the hippocampus is enhanced after nicotine infusion
30
, and that chronic 
nicotine administration in the hippocampus enhances BDNF mRNA expression, 
while acute nicotine administration reduces it
31
. This suggests that the 
association between up-regulation of BDNF and nicotine use might be related to 
the amount and duration of smoking. It has been suggested that acute nicotine 
might increase 5-HT release in the hippocampus
59
 and 5-HT2A receptors regulate 
BDNF expression negatively, thus acute nicotine could decrease hippocampal 
BDNF gene expression by indirectly activating 5-HT2A receptors. Alternatively, 
acute nicotine has inhibitory effects; however, after chronic administration, 





In humans, smoking-BDNF research is sparse. There is some evidence 
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clinical and clinical studies are consistent with our findings of increased levels 
of serum BDNF in smokers. However, smoking-BDNF causal association 
cannot be established from our findings because of the cross-sectional design of 
the current study. Longitudinal investigations that examine changes over time in 
serum BDNF levels after smoking initiation or quitting are warranted in 
shedding light on smoking-BDNF link. 
 
Our findings are inconsistent with one study showing that nicotine-
dependent smokers, with no history of psychiatric or substance-related disorder, 
had lower levels of serum BDNF as compared to non-smokers
60
. However, one 
reason of this discrepancy in findings might be a low sample size (16 nicotine-
dependent smokers, and 13 non-smokers) of this study. 
 
An important limitation of the present study is that it is cross-sectional, 
so a causal association between BDNF and smoking cannot be established. 
Secondly, serum BDNF levels may not accurately reflect central BDNF levels, 
although previous animal research has shown a strong correlation between 
serum BDNF levels and cortical BDNF
16
. Thirdly, results of the present study 
on serum BDNF cannot be generalized to the studies conducted on BDNF stored 
in plasma or platelets because plasma BDNF is circulated in platelets with 200 
fold less concentration than serum BDNF. Finally, the effect of other hormones, 
receptors or neurotransmitters and their interaction with serum BDNF were not 
taken into account which might influence our results
61
. Despite these limitations, 
the present study, with a fairly large sample size, highlights the need of 
investigating longitudinally smoking and BDNF link in human, taking into 
account nicotine dependence. We were also able to control our analyses for the 
diagnosis of an affective disorder (depression or anxiety) because stress, 
depression and anxiety have often been associated with central and peripheral 
reductions of BDNF levels in animals and human
36, 38, 39, 62-64
. Understanding of 
the mechanisms linking smoking and BDNF, the present study may have 
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Background. Previous studies on attentional bias in smokers reported such bias in 
both the initial orienting and maintenance phases of attention, but findings are 
inconsistent. Attentional control may modulate the attention-capturing effects of 
distracting information. The aim of this study is to investigate attentional bias 
across phases of information processing and the role of attentional control in each 
of these phases. 
 
Methods. A dot-probe task with smoking-related and neutral pictures was tested in 
24 smokers and 19 non-smokers. Stimulus-onset asynchronies (SOAs) were 100 ms, 
500 ms, and 900 ms. Multivariate analyses were conducted to examine group 
differences in attentional bias. Correlations and linear regression analyses were 
performed, respectively, to examine the direction of the association between 
attentional bias and attentional control, and the moderation of attentional control 
on attentional bias. 
 
Results. Although smokers seemed to direct their attention preferentially to 
smoking-related pictures in all three SOA conditions, the effects were non-
significant, except in the 900 ms SOA condition where the effect was statistically a 
trend. Attentional control did not moderate the effects, but a significant negative 
correlation was found between attentional control and attentional bias to smoking-
related pictures presented for 100 ms in both smokers and non-smokers. Such 
negative correlation between attentional control and overall attentional bias was 
found only for smokers. 
 
Conclusions. Attentional bias to smoking-related stimuli seems to depend on the 
phase of information processing and on attentional control and these factors should 
be considered in future research of cognitive bias in smoking and addiction. 





Smoking is associated with a bias in the cognitive processing of 
smoking-related cues. The urge to smoke in smokers may be triggered by 
exposure to smoking-related sensory stimuli, such as an ashtray or a lit cigarette. 
These urges may be strengthened by a preferential allocation of attention to 
these cues
1, 2
. Such attentional bias to smoking-related stimuli has been widely 
investigated with the modified version of the Stroop task and the dot-probe task. 
In the modified Stroop task, participants are instructed to color-name smoking-
related words and control words presented in different colors
3-6
 or to make a 
motor response to the color of the word by using a button-press while ignoring 
the semantic content of the word
7-10
. Slower response to smoking-related words 
is assumed to indicate the inability to ignore the semantic content which slows 
down the color-naming. In the dot-probe task, a smoking-related picture and a 
non-smoking-related picture are presented simultaneously. After the offset of the 
pictures, a probe (usually an asterisk or a dot) appears immediately in the 
position of one of the pictures until the participant makes a response. Attentional 
bias towards smoking-related cues is inferred when the participant responds 
faster towards probes that replace the smoking-related picture. This has been 
demonstrated in a number of studies
1, 2, 11-16
. Studies using eye tracking have 
also shown that smokers shift their attention towards smoking-related cues and 





Cue-target delay or stimulus onset asynchrony (SOA) may influence 
attentional bias to smoking-related cues. In order to examine biases in initial 
orienting and in maintenance of attention, studies have used short and long 
SOAs and obtained different results. For example, one study reported a bias in 
maintenance of attention: smokers showed a significantly greater attentional bias 
than non-smokers for smoking-related pictures presented at a stimulus duration 
of 2000 ms. However, no group differences were found at the stimulus exposure 
duration of 200 ms
15
. An eye-tracking study found that the gaze duration of 
smokers on smoking-related pictures was longer than that on the control pictures 
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suggesting a bias in the maintenance of attention on smoking-related cues
1
. 
Another study, however, reported bias in initial orienting of attention: active 
smokers showed a greater attentional bias toward smoking-related cues in short 
SOA of 200 ms but not in trials with a longer SOA of 550 ms
19
. One study 
found attentional bias both in initial orienting (stimuli presented for 200 ms) and 
in maintenance of attention (stimuli presented for 2000 ms)
20
. Individual 
differences in smoking behavior may moderate the effects and may explain 
some inconsistencies in the findings. For instance, a history of unsuccessful quit 





This attentional tendency may be involved in maintaining drug-seeking 
behavior and may also precipitate relapse after quitting. The incentive-
sensitization theory
21
 states that the mesotelencephalic dopamine reward system 
becomes sensitized by repeated use of addictive drugs, and in turn, gives these 
drugs and drug-related stimuli an incentive salience. This makes the perceptual 
and mental representation of these stimuli also highly salient and capable of 
capturing attention. With repeated drug use the act of drug-taking and drug-
associated stimuli, gradually become more and more desirable, which evolves 
into obsessive craving and this is manifested behaviorally as compulsive drug-
seeking and drug-taking.  
 
In a related psychopharmacological model of attentional bias in drug-
abusers
22
 it is proposed that due to increased dopamine release, attentional bias 
to drug-related cues will first activate craving for the drug of abuse, and then 
attentional bias and craving begin to reciprocally modulate each other. This 
theory has gained some support in recent research
1, 23
. Franken’s model further 
suggests that attentional bias may maintain the addictive behavior by enhancing 
the perception of drug-related cues in the environment, increasing drug-related 
cognitions for the cues and making it difficult to draw attention away from them. 
Finally, the attentional resources left for competitive cues are depleted because 
of the limited capacity of attention. Since this process is involuntary, it is 
difficult for the addict to apply attentional resources to prevent relapse
22
. To 
summarize, smoking is associated with enhanced processing of smoking-related 
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stimuli, and this processing may be affected by stimulus presentation-time. This 
processing is also assumed to be important in the maintenance of drug, and in 
the relapse to smoking after quitting. 
 
Attentional control is the ability to use executive functioning to 
selectively keep focus on task-relevant stimuli and to hinder interference from 
distracting, task-irrelevant stimuli
24
. The efficiency of this inhibition function of 
attentional control may be reduced in high-anxious individuals, who as 
compared to low-anxious individuals, found it difficult to inhibit processing of 
task-irrelevant threatening stimuli on an anti-saccade task, thus having impaired 
inhibition
25
. This suggests that attentional control might help reducing anxiety 
by disengaging a person’s attention from threat. The impaired attentional control 
in anxious individuals is conceptualized as the disruption of the balance between 
two attentional systems, the goal-driven and the stimulus-driven attentional 
systems
26
. Because of the increased activation of the stimulus-driven attentional 
system and decreased functionality of the goal-directed attentional system, 




Individual variation in attentional control may determine the presence 
or absence of attentional threat bias. For example, individuals high in trait 
anxiety and low in attentional control showed enhanced processing of threat-
related stimuli (probably because of the deficit in their voluntary attentional 
system) whereas those with high trait anxiety but better attentional control were 
able to disengage their attention from threat-related cues in a spatial-cueing 
task
28
. Similarly, individuals with high trait anxiety and poor attentional control 
had difficulty in ignoring task-irrelevant threat-related emotional pictorial 
stimuli
29
. In healthy volunteers low attentional control was associated with the 
distracting effect of task-irrelevant emotional cues
30
. In a dot-probe task, high 
posttraumatic stress symptoms were associated with threat-related attentional 
bias in trials with longer SOA (500 ms), suggesting difficulty in disengaging 
from threat stimuli. In trials with short SOAs (150 ms), however, attentional 
control moderated the relationship between the stress symptoms and threat bias; 
participants with high stress symptoms and high attentional control were able to 
disengage and shift their attention from the threat stimuli
31
. Consistently, in 
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children with good ability to regulate attention, threat-related bias was unrelated 
to anxiety symptoms. In this study, the SOA of 500 ms was used in a dot-probe 
task that used images of neutral, happy and angry facial expressions
32
. Similar 
attentional bias to threatening words in those with low attentional control has 
also been observed in studies using emotional Stroop task in individuals with 
general anxiety symptoms
33
 and attachment anxiety
34
. In conclusion, individual 
differences in attentional control may influence the processing of task-irrelevant 
threatening stimuli. 
 
The present study will extend this previous research of the association 
between attentional bias and attentional control by investigating the moderating 
role of attentional control on smoking-related attentional bias in smokers. This 
issue has not been addressed before. We will, first, replicate previous findings of 
attentional bias to smoking-related stimuli using three different stimulus 
presentation-times (SOAs), and then will examine whether attentional control 
moderates the association between smoking and smoking-related attentional 
bias. 
 
In this experiment, the pictures were presented in three SOAs, that is, 
100 ms, 500 ms, and 900 ms to examine whether smokers have attentional bias 
to smoking-related pictures in initial orienting and / or in the maintenance of 
attention. Previously, attentional bias in smokers to such pictures in a visual 
probe task has been investigated using long stimulus exposure durations such as 
500 ms or 2000 ms
2, 16, 20
 which may not provide an indication of attentional bias 
in initial orienting. Our study uses much shorter stimulus duration of 100 ms 
which is likely to reflect initial orientation in attention. The two longer SOAs, 
that is, 500 ms and 900 ms may reflect maintenance of attention on smoking-
related cues. We hypothesized that smokers would show an attentional bias in 
initial orienting and in maintenance of attention to smoking-related cues; that is, 
attentional bias would be evident in all three SOAs in smokers. We also 
hypothesized that attentional control would moderate the association of 
attentional bias to smoking-related cues, such that smokers with low attentional 
control would have greater bias to smoking-related stimuli as compared to those 
with high attentional control. 






Participants were Leiden University students who were recruited 
through advertisements and they participated in the study in exchange for a 
partial fulfillment of course credits or a small financial compensation. Inclusion 
criteria were an age between 18 and 35 years, right-handedness, normal or 
corrected-to-normal vision, fluency in Dutch or English, and no current or 
lifetime history of any psychiatric or neurological disorder. Smokers had to 
smoke at least 10 cigarettes per day for more than 1 year. Selection criteria for 
non-smokers were never having experimented with smoking.  
Materials 
 
Visual dot-probe task 
 
To program a dot-probe task, we used the same stimuli as were used in 
Bradley et al.
2
. The stimuli consisted of 16 colored smoking-related pictures 
(e.g., a woman smoking a cigarette, an ashtray with a cigarette next to it) paired 
with a photograph of a similar matching scene that did not include any cigarette-
related content (e.g., a woman applying lipstick, a bowl with a pen next to it). 
Additional eight picture-pairs unrelated to smoking were used for practice trials. 
The task consisted of two blocks: a practice block and an experimental block. 
The practice block included 16 trials; if the participant consecutively made 8 
correct responses they were directed to the experimental block which consisted 
of 288 trials (of which 96 were filler trials). Each trial started with a black 
central fixation cross on a white background for 500 ms. It was followed by an 
inter-stimulus interval of 500 ms, after which a picture-pair was presented. 
Then, a probe in the form of either “one dot” or “two dots” appeared in the 
position of one of the pictures. Participants were instructed to press as fast and 
as accurate as possible the upward arrow key on the computer keyboard if they 
saw the one-dot probe, and the downward arrow key if they saw the two-dot 
probe. There were three presentation-times (SOAs) for the picture-pair (100 ms, 
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500 ms, 900 ms). Congruency (probe occurring in the location of the smoke-
related or the non-smoking related picture), probe type (one or two dots), probe 
position (left or right), and SOA were fully counterbalanced. Picture-pairs were 
chosen randomly. The inter-trial interval varied randomly between 400 ms and 
1000 ms. Unlike in the study by Bradley et al.
2
 the trials with different short and 
long SOAs occurred in a random order in blocks of 48 trials. After each block 
there was a break that lasted 40 seconds. Intermixing short and long SOA trials 
randomly in a block would reduce the likeliness that participants form temporal 
expectations for the target stimuli
19
. Half of the smoking-related pictures were 
congruent with the location of the probe, whereas the other half were not. 
Additionally, in half of the trials the probe was presented in the left side of the 
screen and in the other half on the right side. The task took overall about 15 
minutes to complete. 
 
Attentional Control Scale 
 
The attentional control scale (ACS) is a 20-item self-report 
questionnaire
28
. It assesses the ability to focus attention and resist unintentional 
shifting to irrelevant or distracting information (e.g., my concentration is good 
even if there is music in the room around me), to shift attention while avoiding 
unintentional focusing on irrelevant information (e.g., it is easy for me to read or 
write while I’m also talking on the phone), and to flexibly control thought (e.g., 
I can become interested in a new topic very quickly when I need to). All items 
are scored on a 4-point Likert scale from ‘1’ (almost never) to ‘4’ (almost 
always) with higher scores indicating better attentional control. Some items are 
reversed scored. 
 
Positive and Negative Affect Schedule 
 
The positive and negative affect schedule (PANAS) is a self-report 
questionnaire. It consists of 20 items, 10 assessing participant’s positive affect 
(PA) and the other 10, negative affect (NA). It is rated on a 5-point scale (0 = 
not at all, 4 = extremely). PA represents the extent to which an individual 
experiences pleasurable engagement with the environment. Examples of 
emotions indicative of high PA are excitement, determination, and alertness. NA 
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shows the extent to which an individual shows subjective distress and 
unpleasurable engagement. Thus, emotions such as irritability, distress, and 
hostility manifest high NA
35
. The reliability and validity of PANAS have been 





Participants who responded to the advertisement were first screened by 
telephone or email for eligibility to participate in the study. On arrival, 
participants were given brief verbal instructions on all of the tasks that they 
would be participating in, after which they signed a written informed consent. It 
was followed by a standardized protocol that included detailed instructions on 
how to do the tasks. In about 35-minute testing session participants were 
required to complete two computerized tasks and to fill in a number of 
questionnaires. They were taken to a quiet, well-lit experimenter chamber and 
seated 40-45 cm from the computer screen to complete a visual probe task and 
to fill in the ACS. The tasks were designed in e-prime (v.2) and were presented 
on a 17-inch CRT monitor. After completing the computerized tasks, 
participants filled in a number of questionnaires that were used to collect their 
demographic data, smoking behavior, and baseline mood. Participants received 
either monetary rewards or course credits for their participation. 
 
This study was approved by the Ethics Committee of the Institute of 
Psychology at Leiden University and was carried out in compliance with the 
Helsinki Declaration. 
Data Reduction and Statistical Analyses 
 
Data with erroneous responses (2.5 %) and reaction times (RTs) of the 
filler trials were discarded (33 %). Outliers were removed by, first, excluding 
from the analyses all RTs less than 200 ms and greater than 2000 ms (0.2 %). 
Then, RTs more than 3 standard deviations (SDs) above or below each 
participant’s mean were excluded (1.2 %). Smokers and non-smokers were 
significantly different in number of errors and outliers (ps < 0.001) with smokers 
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having greater number of errors and outliers. However, there were no 
differences in the errors on congruent and incongruent trials (p > 0.05) and on 
trial type.  
 
After data cleaning, preliminary analyses were conducted to ensure no 
violation of the assumptions of univariate and multivariate tests. Participants’ 
characteristics were evaluated by independent-samples t-test and chi-square test 
for independence. Cohen’s d was used as a measure of effect size for significant 
associations. For each participant, mean RT was calculated for both the 
congruent and the incongruent trials in all three SOA conditions. Attentional 
bias score was then calculated for each participant by subtracting the congruent 
trials from the incongruent ones, and these bias scores were calculated 
separately for each SOA condition. A positive value, thus, reflects faster RTs 
when the probe replaces smoking-related stimuli. Overall attentional bias was 
calculated for each participant by averaging their bias scores representing the 
three SOAs. We will use the following abbreviations: AB100ms, AB500ms, 
AB900ms, and overall AB. A multivariate analysis of variance (MANOVA) was 
run on the bias scores to examine the difference between smokers and non-
smokers in attentional bias to smoking-related pictures presented at three 
different durations. To examine group differences in overall attentional bias, an 
independent-samples t-test was run. The relationship between attentional bias 
and attentional control was further explored using Pearson product-moment 
correlation coefficient. These analyses were followed by running separate 
correlations for smokers and non-smokers. Finally, we conducted separate 
hierarchical linear regressions for overall AB and then separately for AB100ms, 
AB500ms, and AB900ms, in order to examine the moderation of attentional 
control on attentional bias and smoking. For each regression analysis, the 
dependent variable was the attentional bias score, the predictor was smoking 
status, and the moderator was the score on the ACS. The moderator was 
centered to the mean to reduce multicollinearity
37
. The first model of linear 
regression included smoking status. The second model added attentional control, 
and the third model included the product variable representing the interaction 
between smoking status and attentional control. For two participants (a smoker 
and a non-smoker) the z-score of the mean attentional bias index on some 
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stimulus exposure conditions and on overall AB was above 3. Thus, we first ran 
the analyses without these outlying cases, and then repeated all the analyses in 
the whole sample 
a
. All analyses used an alpha level of .05. Analyses were run 





Forty-three students (19 non-smokers, 24 smokers; age-range: 18-35 
years; Mean = 22.5 years, SD = 4.0) participated in the experiment. Table 1 
shows that smokers and non-smokers were not different significantly on 
demographic and clinical variables and attentional control (ps > 0.05). 
 
Table 1. Participants’ characteristics 
    
 Non-smokers Smokers p 
 N = 19 N = 24  
    
Age (Mean, SD) 21.5 4.0 22.9 4.6 ns 
Gender, female (N, %) 14 74 16 67 ns 
Education (N, %)     ns 
    -basic 13 68,4 15 62.5  
    -intermediate 5 26,3 9 37,5  
    -high 1 5.3 0 0  
PANAS-PA
†
(Mean, SD) 31.4 7.9 31.0 6.2 ns 
PANAS-NA
†
(Mean, SD) 14.0 4.1 14.2 4.0 ns 
ACS
†
(Mean, SD) 54.9 9.2 53.3 7.3 ns 
      
*p < 0.05 
†
PA: scores on the positive affect sub-scale of the PANAS; NA: scores on the 








Group Differences in Attentional Bias to Smoking-Related 
Pictures 
 
MANOVA showed a trend of smoking status on attentional bias in the 
900 ms SOA condition (F (1, 39) = 3.1; p = 0.08; partial η
2
 = 0.07) while a non-
significant effect on the 500 ms (p = 0.1) and 100 ms (p = 0.2) SOA conditions. 
However, the pattern of the association between smoking status and attentional 




Figure 1a. Attentional bias to smoking-related stimuli in  
smokers and non-smokers 
 
larger bias score (M =17.0; SD = 30.7) for the smoking-related pictures than 
non-smokers (M =1.6; SD = 23.7). A significant group difference was found for 
overall AB (t (39) = -2.4; p = 0.02; Cohen’s d = -0.8) with smokers having larger 




The Relationship Between Attentional Control and 
Attentional Bias  
 
Pearson product-moment correlation indicated that attentional control 
was significantly but negatively correlated with AB100 ms (r = -0.46; N = 40; p  
= 0.003) and with the overall AB (r = -0.31; N = 40; p (two-tailed) = 0.054). 
There was no correlation of attentional control with AB500ms and AB900ms 





Figure 1b. Smoking-related attentional bias in smokers and non-smokers 
with high and low attentional control 
 
smokers attentional control was negatively correlated with AB100ms (r = -0.42; 
N = 22; p (two-tailed) = 0.054) and with overall AB (r = -0.42; N = 22; p (two-
tailed) < 0.051). In non-smokers, attentional control was negatively correlated 
with AB100ms (r = -0.46; N = 18; p (two-tailed) = 0.053). Other correlations of 
attentional control with AB500ms and AB900ms were non-significant in both 
groups (ps > 0.05). Figure 1b shows the mean overall attentional bias scores for 
the smoking groups with low and high attentional control. As can be seen that 
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smokers with low attentional control have high attentional bias to smoking-
related pictures than those with high attentional control, and smokers have high 
overall attentional bias than non-smokers. 
 
Table 2 shows the results of linear regression models. Regression 
analysis with AB100ms as the dependent variable showed that the first model 
with smoking status as predictor explained no significant variance in attentional 
bias (p > 0.05). In the second model when we added attentional control, 27.8 % 
of significant overall variance was explained in the dependent variable (R
2
 
change = 0.26; p = 0.001). The third model that added the interaction term of 
smoking status and attentional control, did not account for a significant variance 
in AB100ms (p > 0.05). Regression analyses with AB500ms and AB900ms 
were non-significant (ps > 0.05). Regression analysis with overall AB as the 
dependent variable showed that the first model with smoking status explained 
13.0 % of significant variance in overall AB (p < 0.05). The second model with 
attentional control explained an additional 7.0 % of the variance in the outcome 
variable, showing a trend (R
2 
= 20.0; p = 0.08). The final model with the 






Table 2. Predictors of attentional bias 
 R2 R2 Change B SE β 
Overall attentional bias 
Model 1 .13 .13*    
Smoking status   14.4 6.0 .36* 
Model 2 .20 .07    
Smoking status   13.0 5.9 .33* 
Attentional control   -0.7 0.4 -.27 
Model 3 .22 .02    
Smoking status   13.0 5.9 .33* 
Attentional control   -0.3 0.5 -.14 
Interaction of smoking status and 
attentional control 
  -0.7 0.8 -.18 
Attentional bias (100 ms) 
Model 1 .02 .02    
Smoking status   8.7 10.7 .13 
Model 2 .28 .26***    
Smoking status   5.2 9.4 .08 
Attentional control   -2.2 0.6 -.51*** 
Model 3 .29 .01    
Smoking status   5.2 9.4 .08 
Attentional control   -2.6 0.8 -.61** 
Interaction of smoking status and 
attentional control 
  0.9 1.2 .15 
Attentional bias (500 ms) 
Model 1 .01 .01    
Smoking status   7.3 11.3 .10 
Model 2 .05 .04    
Smoking status   6.1 11.3 .09 
Attentional control   -0.9 0.7 -.21 
Model 3 .06 .002    
Smoking status   6.1 11.4 .09 
Attentional control   -0.7 0.9 -.17 
Interaction of smoking status and 
attentional control 
  -0.4 1.4 -.06 
Attentional bias (900 ms) 
Model 1 .07 .07    
Smoking status   15.4 8.9 .27 
Model 2 .07 0    
Smoking status   15.4 9.1 .27 
Attentional control   -0.002 0.6 -.001 
Model 3 .08 .01    
Smoking status   15.4 9.2 .27 
Attentional control   0.3 0.8 .09 
Interaction of smoking status and 
attentional control 
  -0.7 1.2 -.13 
      
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001      





We investigated attentional bias to smoking-related pictures in smokers 
and non-smokers. The pictures were presented for 100 ms, 500 ms, and 900 ms. 
We also examined the moderating role of attentional control on attentional bias 
to smoking-related pictures in the groups. 
 
The main findings of the study were that smokers had higher overall 
attentional bias score than non-smokers. No significant group differences were 
observed when pictures were presented for 500 ms and 100 ms, whereas the 
difference between smokers and non-smokers in attentional bias was a trend 
when pictures were presented for a longer stimulus duration of 900 ms. These 
findings, though showing a trend, are suggestive of a bias in the maintenance of 
attention, but not in initial orienting. We did not find a moderation or interaction 
of attentional control on attentional bias to these stimuli. However, we did find a 
strong, negative correlation of attentional control with attentional bias to 
smoking-related stimuli presented for 100 ms and with the overall attentional 
bias score. Smokers with low attentional control have high overall attentional 
bias and attentional bias to smoking-related pictures presented for 100 ms. This 
suggests that the effect of attentional control on attentional bias is more 
prominent when stimuli are presented briefly. Such negative correlation, though, 
was also found for non-smokers when stimuli were presented for 100 ms. Thus, 
the data indicate that in individuals with low ability to regulate attention, 
involuntary attentional capture by smoking-related cues is increased. Later in the 
discussion, we would mention a possible reason of attentional bias in non-
smokers for smoking-related pictures presented at a duration of 100ms. 
 
Our research is in agreement with the attentional maintenance or 
disengagement model because it suggests that smokers have difficulty to 
disengage their attention from smoking-related picture once fixated on it. 
Several studies investigating smoking-related attentional bias have found 
evidence for a bias in maintenance of attention but not in initial orienting
1, 15
. 
Bias in maintenance of attention has also been reported in studies in alcoholics 
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and other drug users. For example, in heavy social drinkers, attentional bias for 
alcohol-related cues displayed for 200 ms was not evident, however, it was 
apparent at longer stimulus durations of 500 ms and 2000 ms
23
. However, few 
studies found evidence of attentional bias, both, in initial orienting and in the 
sustained attention
2, 20
. This discrepancy in findings may be due to smokers 




The negative correlation between attentional control and attentional bias 
to smoking-related pictures presented for 100 ms indicates that the present 
results are also consistent with research showing initial orienting in attention to 
smoking-related cues
19
 but only in smokers with low attentional control. Such 
association, however, was found for non-smokers as well. One explanation of 
these results could be that a bias to smoking-related stimuli presented for 100 ms 
may have been induced in non-smokers at the time of screening (when they 
were asked questions about their smoking behavior, which may have made 
smoking-related stimuli more salient), but only in those with low attentional 
control. This statement can be supported by a study showing that when non-
smokers were aware of the presence of smoking-related stimuli in the 
experiment, they displayed the same attentional bias as the smokers, but not 




The neurobiological mechanisms underlying smoking-related 
attentional bias are largely unknown. The incentive salience that smoking and 
smoking-related stimuli have acquired by repeated nicotine use makes the 
dopamine reward system sensitized, which, in turn, makes these stimuli highly 
salient and capable of capturing attention, leading to drug-seeking and drug 
maintenance with repeated exposure to the drug
21
. It has been shown that 
attenuating dopamine levels in smokers by acute tyrosine and phenylalanine 
depletion, was associated with the reduction of attentional bias overtime to 
smoking-related words
39, 40
. Moreover, the reduction of dopamine levels by 
D2/D3 dopamine antagonist haloperidol reduced the enhanced brain activation 
associated with attentional bias to smoking-related pictures, leading to no-
difference in brain activation between smokers and non-smokers
41
. Similarly, 
the increase in attentional bias and the activation of associated brain areas was 
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associated with the administration of dopamine D2/D3 receptor agonist 
pramipexole dihydrochloride in high compulsive stimulant-dependent 
individuals
42
. At a speculative level, these studies can be extended by 
investigating group differences in the reduction or increase of attentional bias 
and related brain activation as a result of decreasing or increasing dopamine 
levels by administering dopamine antagonist/ agonist in smokers with low and 
high attentional control. Further, nicotine deprived smokers show greater 
processing bias
43
, thus it would be helpful to experimentally manipulate craving 
to examine the effect of attentional control on the processing of these cues when 
there is an increased urge to smoke. Moreover, using eye tracking or event-
related potential measures, the present research can be replicated and extended 
to investigate, for example, in more detail whether individual differences in 
attentional control modulate attentional bias in initial orienting to smoking-
related cues or in maintenance of attention on these cues. The incentive-habit 
theories of addiction that are supported by studies showing that low levels of 
nicotine dependence have been associated with high attentional bias for 
smoking-related cues
18
 can be further investigated taking into account individual 
differences in attentional control. 
 
Our study suggests that there may be differences among smokers in 
their attentional processing of smoking-related cues, in their vulnerability to 
smoking, and their risk of relapse after quitting, and these may be mediated by 
their ability to control attention. Thus, the present results may have implications 
for understanding the mechanisms by which smokers relapse to smoking after 
quitting. 
 
These results may be evaluated in light of the following limitations. 
Firstly, nicotine deprivation was not manipulated, so urge to smoke may not be 
very high in many participants which may have polluted the results because 
variables such as recency of smoking may vary across smokers. Secondly, we 
recruited participants who smoked 10 or more cigarettes per day, thus, not 
controlling for variation in smoking behavior between light and heavy smokers. 
Despite these limitations, this study is important because it investigates 
smoking-related attentional bias while taking into account attentional control. 
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This issue has not been addressed before. Another merit of the study is that we 
were able to assess participants’ mood, given that smoking is closely associated 
with negative mood
44




To summarize, regardless of their attentional control, the present study 
indicates that smokers seemed to direct their attention to smoking-related 
pictures when presented under conditions where multiple shifts in attention were 
possible. However, when the stimulus presentation-time was short, smokers 
showed reflexive and automatic attention to smoking-related stimuli only when 
they had low attentional control. (Similar association between initial orienting in 
attention and attentional control in non-smokers may be due to their awareness 
of the presence of smoking-related stimuli in the experiment). However, this 
later finding has been shown only by correlation, and the univariate and 
multivariate analyses and regression models did not show any interaction or 
moderation between attentional control and attentional bias. 
 
This study may have important implications for smoking cessation. For 
example, attentional bias modification (ABM) may be most suitable for smokers 
low in attentional control and may reduce attentional bias for smoking-related 
stimuli thus resulting in alleviating craving in addicted smokers; however, a 
single training session of ABM may not produce desired effects
13
. Moreover, 
individuals with low ability to regulate attention may have hypervigilance to 
smoking-related cues, and may represent a risk group for smoking relapse. 
Following attention training that aimed at strengthening attentional control, 
smokers with more pronounced bias and poor attentional control may more 
likely achieve abstinence and less likely relapse. 
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The adverse health risks/ consequences of smoking
1-4
 and of depression 
and anxiety disorders
5-9
 are well-documented, and these conditions frequently 
co-occur
10-15
. The aim of the present thesis was to further improve our 
understanding of the link between smoking and affective disorders and to 
provide an opportunity to stimulate longitudinal research on smoking-
psychopathology association in order to elucidate the underlying mechanisms of 
this association. This may optimize smoking prevention strategies and 
intervention programs.  
 
In this chapter, we will, first, summarize the findings reported in 
chapter 2 through chapter 6. Then we will discuss the findings within the context 
of the current scientific evidence, and speculate about possible mechanisms 
underlying the main findings. Next, we will point out some methodological 
issues, and address clinical implications of our findings and recommendations 
for future research. Finally, concluding remarks will be presented. 
 
For chapter 2 to chapter 5, we used data from the Netherlands study of 
depression and anxiety (NESDA), while in chapter 6, we collected our own data 
using students from Leiden University. 
Summary of the Findings 
 
1. We first examined, retrospectively, an association of age at the onset of 
smoking with the onset age of depression and/ or an anxiety disorder 
(chapter 2). We selected those participants who had been diagnosed 
with an affective disorder (depression and/ or anxiety) after the onset of 
smoking (N = 1,055). Participants were grouped into early-onset 
(started smoking at 10 to 15 years) and late-onset (started smoking after 
the age of 15 years) smoker. The time period between smoking onset 
and the onset of depression and/or an anxiety disorder was shorter for 
early-onset smokers as compared to late-onset smokers. Within the first 
five years after starting smoking, a greater percentage of early-onset 
smokers than late-onset smokers had the first onset of an affective 
disorder. When we examined this association separately for depression 
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and anxiety disorders, this pattern of results was found only for anxiety 
disorders. The analyses were adjusted for the effects of gender, 
education and childhood trauma. 
2. The effect of smoking and nicotine dependence on the severity and 2-
year course of depressive and anxiety symptoms was investigated 
(chapter 3) in patients with a current (past 6 months) diagnosis of 
depression and/or an anxiety disorder (N = 1,725). The sample was 
categorized into never-smokers, former smokers, non-dependent current 
smokers, and nicotine-dependent current smokers. We found that the 
baseline symptoms of depression, general anxiety, social anxiety and 
agoraphobia were more severe in nicotine-dependent smokers than in 
non-dependent smokers, former and never-smokers. These differences 
remained after adjusting for covariates, except for social anxiety on 
which the groups did not differ when the models were adjusted for 
covariates. Over a two-year follow-up, nicotine-dependent smokers 
improved their symptoms of depression and anxiety disorders at a 
slower rate than the other groups, even after controlling for covariates. 
No differences between the groups in the course of symptoms of social 
anxiety and agoraphobia were observed over time. Thus, in psychiatric 
patients, smoking is associated with higher severity of depressive and 
anxiety symptoms, and with slower recovery, but only when smokers 
are nicotine-dependent. 
3. The mechanisms underlying the well-established association of 
smoking and nicotine dependence with depression and anxiety disorders 
are unclear. In chapter 4, we investigated the interaction between the 
BDNF gene Val
66
Met polymorphism and smoking status with symptom 
severity of depression and anxiety disorders. We selected the same 
NESDA sample (N = 1,271), having a current diagnosis of an affective 
disorder, and it was stratified into never-smokers, former smokers, and 
current smokers with and without nicotine dependence. The results 
revealed that in the patients who carried the Val
66
Val genotype of the 
BDNF Val
66
Met polymorphism nicotine-dependent smokers had more 
severe symptoms of depression and anxiety than non-dependent 
smokers, former smokers, and never-smokers, whereas the latter three 
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groups were comparable on symptom severity. In Met
66
 carriers, 
however, there were no differences among the four smoking groups on 
severity of depression and anxiety. Regarding the symptoms of social 
anxiety and agoraphobia, the BDNF genotype had no effect. Nicotine 
dependence was the strongest predictor of severity of symptoms only in 
Val
66
Val carriers. Thus, the relationship between nicotine dependence 
and symptom severity in patients with an affective disorder  may be 
moderated by the BDNF Val
66
Met polymorphism. 
4. Both smoking and psychopathology are associated with serum brain-
derived neurotrophic factor. In an attempt to elucidate the mechanisms 
underlying smoking-psychopathology association, we examined, in 
chapter 5, the levels of serum BDNF in never-smokers, former smokers 
and current smokers with and without nicotine dependence (N = 2,088) 
while controlling for age, sex, education, alcohol use, physical activity, 
recent negative life events, body mass index, the use of anti-
depressants, and the diagnosis of a affective disorder. We also examined 
the interaction of the polymorphism and smoking status with serum 
BDNF. We found that current smokers with and without nicotine 
dependence had higher levels of serum BDNF than the non-smoking 
groups of former and never-smokers who were comparable in their 
serum BDNF levels. Similarly, the two current smoking groups with 
and without nicotine dependence were comparable in serum BDNF. 
Nicotine dependence and number of cigarettes smoked per day were not 
significant predictors of serum BDNF. However, total smoking years 
was a predictor of serum BDNF. Thus, regardless of smoking severity, 
current smoking was associated with higher serum BDNF levels. In 
contrast,  in NESDA un-medicated depression was weakly  associated 
with decreased levels of serum BDNF
16
. This opposite pattern of 
associations for BDNF does not make it very likely that the smoking-
depression association is driven by underlying BDNF mechanisms. 
Further, we also did not find an interaction of BDNF genotype and 
smoking status on serum BDNF, suggesting that BDNF Val
66
Met 
polymorphism did not further contribute to the smoking-serum BDNF 
association. In all, these results further suggest that serum BDNF may 
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not be a linking mechanism in the smoking-psychopathology 
association. 
5. Attentional control, the ability to focus attention on task-relevant 
stimuli, and to inhibit interference from distracting stimuli, may be 
another potential mechanism underlying smoking-psychopathology 
association. To date, there is no study that investigated attentional 
control as a mechanism underlying smoking-psychopathology 
association. Previous research has been done on attentional control and 
threat related attentional bias, and it has been shown that anxious 
individuals with poor attentional control have inefficient ability to 
divert their attention from threat-related stimuli, and thus are unable to 
cope with their anxiety. The initial step to investigate the role of 
attentional control in smoking-psychopathology association would be to 
investigate the role of attentional control in attentional bias to smoking-
related cues (chapter 6), as this issue has not been addressed before. 
Smoking-related attentional bias in both the initial orienting and in the 
maintenance phases of attention has been reported. Attentional control 
may modulate the attention-capturing effects of distracting information. 
In chapter 6, we investigated attentional bias across information 
processing phases and the role of attentional control in each of these 
phases using a dot-probe task with smoking-related and neutral pictures 
in smokers and non-smokers (N = 43; 24 smokers). The pictures were 
presented for 100 ms, 500 ms, and 900 ms. The main findings of the 
study were that smokers had higher overall attentional bias score than 
non-smokers. However, when pictures were presented for 500 ms and 
100 ms, no significant group differences were observed. In longer 
picture-presentation duration of 900 ms, the group difference in 
attentional bias was a trend. These findings are suggestive of a bias in 
the maintenance of attention, but not in initial orienting. We did not find 
a moderation or interaction of attentional control on attentional bias to 
these stimuli. However, we did find a strong, negative correlation of 
attentional control with attentional bias to smoking-related stimuli 
presented for 100 ms and with the overall attentional bias score. 
Smokers with low attentional control have high overall attentional bias 
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and attentional bias to smoking-related pictures presented for 100 ms. 
This suggests that the effect of attentional control on attentional bias is 
more prominent when stimuli are presented briefly. Such negative 
correlation, though, was also found for non-smokers when stimuli were 
presented for 100 ms. Thus, the data indicate that in individuals with 
low ability to regulate attention, involuntary attentional capture by 
smoking-related cues (or any salient cues) is increased. The presence of 
attentional bias to smoking-related stimuli seems to depend on the phase 
of information processing and on attentional control. 
Explaining Smoking-Psychopathology Linking 
Mechanisms/ Risk Factors 
 
Research on the relationship of smoking with depression and anxiety 
has reported a two-way smoking-psychopathology association, such that some 
studies have found that depression and anxiety precedes the onset of smoking 
behavior
17-21
, whereas other studies have reported a subsequent onset of or 
higher risk of depression and/ or an anxiety disorder after starting smoking
22-26
. 
Some longitudinal studies have found a bi-directional association in which both 
the conditions mutually influence each other
27-30
. These studies lead to the 
formulation of three theories: (i) smoking may serve as self-medication to 
ameliorate depressive or anxious symptoms
31, 32
, (ii) smoking is a vulnerability 
factor in the development of depression and/or anxiety disorders
33
, and (iii) both 
smoking and negative affect may be due to common vulnerability factors
27, 34
. 
These theories are not mutually exclusive; in fact all three may be true. Below 
we discuss some factors, from our research and from the previous investigations, 
which may potentially influence smoking-psychopathology association: 
 
Age at the Time of Nicotine Exposure 
 
Our findings suggest that the age at which an individual starts smoking 
may be crucial to determine whether or not an individual will experience 
aversive mood states later in life. In early-onset smokers, not diagnosed with 
depression or anxiety at the onset of smoking, the time to the onset of a disorder 
                                               General Discussion 
 
 157 
after starting smoking, was shorter, than in late-onset smokers. This indicates 
that the brain at a younger age is probably more sensitive to the detrimental 
effects of nicotine which manifests in adverse health outcomes later in life. 
Previous animal and human studies (presented below) have shown that prenatal 




Prenatal or early-age nicotine exposure has adverse effects on the brain 
and mental health later in life. For example, animal studies documented the 





Prenatal nicotine exposure has been shown to cause morphological and 
neurobehavioral abnormalities in the developing brain. Significant reductions in 
neuronal areas of dentate gyrus and the hippocampus
36
 and somatosensory 
cortex
37, 38
 were observed following prenatal nicotine exposure, and it has been 
suggested that these morphological changes may delay neuronal maturation
38
, 
and may contribute to the behavioral abnormalities
36





Similarly, prenatal nicotine exposure acutely reduces and inhibits the 





It also has an effect on development and functionality of catecholamine 
and neurotransmitter systems. It suppresses norepinephrine and dopamine 
levels
40
 and damages serotonergic systems
41
. Deficits in the functioning of 
serotonin and other catecholamine systems emerge or lasted in the brain in 
adulthood
40-43
 suggesting that prenatal nicotine exposure does not only produce 
direct neurodevelopmental damage, but it leads to lasting disruption of the 
functionality of catecholamine and neurotransmitter systems, and these 
dysfunctions contribute to behavioral abnormalities. In the words of Slotkin, it 
“changes the trajectory of brain development, that is, it alters the program for 
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the establishment and functioning of circuits and connections”
35
, and 
“permanently reprograms synaptic activity”
43
, and that “even where some 
synaptic parameters return nearly to control values…this does not necessarily 
represent the restoration of completely normal function but rather can reflect 
adaptations to the initial damage and/or the subsequent change in the 
developmental trajectory of the affected circuits”
35
. Thus, damages due to 
prenatal nicotine exposure are irreversible, and may lead to long-term sequelae 
that persist even after abstinence. 
 
Animal models of depression and anxiety have shown that early-age 




 states in 




In humans, maternal smoking during pregnancy has adverse effects on 
subsequent physical and cognitive development of the child
46-49
. It is associated 
with specific subtypes of attention deficit hyperactivity disorder in genetically 
susceptible children
49-52





, and mood disorders and nicotine dependence
49, 55
 in children. 
 
Research on age at the onset of smoking in humans indicates that 
exposure to nicotine early in life is associated with the development of 
peripheral artery disease
56
, the risk of lung cancer
57
, deviant or atypical smoking 
patterns such as inability to quit and nicotine dependence
58-67
, engagement in 




, alcohol abuse and 
dependence
60, 69




Given the previous research on adverse physical and mental health 
effects of prenatal  and early-age nicotine exposure in animals and humans, it is 
probable that individuals who start smoking at a younger age, may have  an 
increased vulnerability to subsequently experience worse mental health 
outcomes, such as depression and anxiety disorders, specifically that early-age 
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nicotine use produces functional deficits in serotonergic systems
41, 71, 72
 which 






Our findings of high rates of affective symptoms in nicotine-dependent 
current smokers than in non-dependent, former, and never smokers, and slow 
recovery of symptom severity over time in dependent smokers indicate that 
nicotine dependence might be a predisposing factor in smoking-
psychopathology association. Consistent with this, a number of studies has 
reported a dose-response relationship between smoking and affective disorders. 
Severity of depressive and anxiety symptoms has been related to regular 
smoking, frequency of cigarette use, and heavy smoking
22, 32, 81-85
. In an 11-year 
population-based study on adults; the risk of subsequent depression was higher 
for heavy smokers, and smoking chronicity and severity were associated with 
increasing risk of major depression
24
. In a 3-wave community-based prospective 
study, heavy smoking during adolescence was associated with an increased risk 
of generalized anxiety disorder, agoraphobia and panic disorder during early 
adulthood
86
. Similarly, current smokers with nicotine dependence had higher 
levels of depressive and anxiety symptoms than non-dependent smokers
87-89
. In 
a prospective population-based study of young adults, a history of nicotine 
dependence was associated with an increased risk of first-incidence of major 
depression than no history of nicotine dependence
27
. Similarly, nicotine-
dependent smokers at baseline had an increased risk for new onset of panic 
attacks and disorder at 4-year follow-up period
90
 and elevated rates of anxiety 






We further found that only those nicotine-dependent smokers had more 
severe symptoms of depression and anxiety than non-dependent and non-
smoking groups, when they were having the Val
66
Val genotype of BDNF 
Val
66
Met polymorphism. In Val
66
Met carriers, all four smoking groups, that is, 
never-smokers, former smokers, non-dependent current smokers and nicotine-
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dependent current smokers were comparable in symptom severity. The smoking-
psychopathology association has rarely been studied taking into account 
candidate genes. We found two studies that tested, from a genetic perspective, 
the theory of smoking as a self-medicating agent to alleviate depressive 
symptoms. One study (N = 231) found that self-medicating smoking practices 
were significantly heightened in depressed smokers with two short alleles of 
DRD4 gene but not in those heterozygous or homozygous for the long alleles of 
DRD4
92
. In another study, a cohort of 615 adolescents were followed from 9th 
to 11th grade, and the effects of dopamine transporter (SLC6A3) and dopamine 
receptor (DRD2) genetic variants on smoking progression were evaluated. The 
sample was grouped into never-smokers and those who had been exposed to 
nicotine (i.e., smoked at least a puff of a cigarette). Smokers with severe 
depressive symptoms were more likely to progress to a higher level of smoking 
only if they had DRD2 A1 allele. No effects of SLC6A3 on smoking-depression 
association was observed
93
. Thus, these studies suggested that genetic factors 
involved in dopamine transmission may be involved in the rewarding effects of 
smoking. The theory that smoking is a vulnerability factor in depression and 
anxiety has recently been investigated using the rs1051730 SNP variant located 
in the nicotine acetylcholine receptor gene cluster on chromosome 15. The 
participants were selected from a large population-based study, the Norwegian 
HUNT study (N= 53, 601). Self reported smoking was positively associated 
with the symptoms of anxiety and depression, and the polymorphism was 
positively associated with smoking. However, no association of the 
polymorphism with either anxiety or depression was found among smokers
94
 
suggesting that this gene variant is not a predisposing factor to link smoking 
with depression and anxiety. Our results are supportive of, or refine the 
vulnerability theory of smoking-psychopathology association (chapter 4). 
 
We found that only those nicotine-dependent smokers who were 
homozygous for Val
66
Val BDNF genotype, had severe symptoms of depression 
and anxiety. But since, the study is cross-sectional no causal association can be 
established. Both these studies point to elucidate a mechanism but the 
association is a bit more complex. 
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Nicotine Acetylcholine Receptors (nAChRs) 
  
 One of the theories explaining smoking-psychopathology association is 
the self-medication theory. However, nicotine use is not an effective anti-
depressant , given the high prevalence of depressive and anxiety symptoms in 
smokers. Though it has been reported that smoking alleviates negative mood, 
but the effect do not seem to be long-lasting. Smoking may initially improve 
mood, but chronic nicotine use may be associated with worsening symptoms of 
affective disorders. This assumption has been supported by studies showing that 
smoking cessation leads to reduced stress
95
, and that successful quitters 




 One of the neurobiological mechanisms might be nicotine acetylcholine 
receptors (nAChRs) that are molecular targets of nicotine in the brain. nAChRs 
have been intensely studied to elucidate their pathophysiological role in 
mediating addiction to nicotine in tobacco
97-99
. nAChR dysfunctions are also 
implicated in anxiety disorders and depression
100, 101
. It has been shown that 
nicotine use induces hyperactivation of cholinergic signaling, and this 
hyperactivation may lead to depression
102
. This has been demonstrated by 
studies showing that the increase of acetylcholine levels in brain by 
administering cholinesterase antagonist physostigmine resulted in negative 
effects on mood
103
. From these observations, it was suggested that cholinergic 
hypersensitivity may be a risk factor in the onset of depression
104
. Recently, it is 






Attentional control can be defined as the ability to use executive 
functioning to selectively keep focus on task-relevant stimuli and to hinder 
interference from task-irrelevant stimuli
106
. High-anxious individuals find it 
difficult to inhibit processing of task-irrelevant threatening stimuli possibly 
because of the reduced efficiency of the inhibition function of attentional 
control
107
. In order to assess attentional bias to threatening stimuli and to 
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investigate whether attentional control moderates the relationship between 
attentional bias to these stimuli and anxiety symptoms, a number of studies were 
conducted. These studies suggested that individual variation in attentional 
control may determine the presence or absence of attentional threat bias. For 
example, individuals with high trait anxiety and poor attentional control showed 
enhanced processing of threat-related stimuli in a spatial-cueing task
108
 and had 
difficulty in ignoring task-irrelevant threat-related emotional pictorial stimuli
109
 
as compared to those with better attentional control. Other studies also reported 
an association of low attentional control and attentional bias to threatening 
words in individuals with general anxiety symptoms
110





In our study (chapter 6), we expected that attentional control would 
moderate the association of attentional bias to smoking-related cues, such that 
smokers with low attentional control would have greater bias to smoking-related 
stimuli as compared to those with high attentional control. Although, we did not 
find a moderation of attentional control on attentional bias to smoking-related 
stimuli, we did find that low attentional control was correlated with high 
attentional bias to smoking-related pictures presented for 100 ms; however, this 
effect was seen for both smokers and non-smokers. Thus, the data indicate that 
in individuals with low ability to regulate attention, involuntary attentional 
capture by smoking-related cues (or any salient cues) is increased. 
 
It has been suggested that the disruption of the balance between two 
attentional systems, the goal-driven and the stimulus-driven attentional systems, 
may cause this impaired attentional control
112
. In anxious individuals, the 
activation of the stimulus-driven attentional system is increased while the 
functionality of the goal-directed attentional system is decreased. This results in 
the processing of threat-related stimuli to a higher degree
113
. In an earlier 
account of attentional control, there is an involuntary posterior attentional 
system in which attention is, first, disengaged from one point, moved to a 
different point and engaged to the new point where it is facilitated and 
transferred to the voluntary anterior system of attention. The anterior system 
regulates the posterior attentional system, thus it might help reducing anxiety by 
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disengaging a person from threat or diverting his/her attention from it
114, 115
. It 
has been suggested that attentional control is related to the functioning of the 
voluntary anterior attentional system
108
. Thus individuals with poor attentional 
control who show bias in their attention to concern-related stimuli may find it 
difficult to inhibit processing of task-irrelevant stimuli probably because of the 
deficit in their voluntary attentional system. 
 
Here, it should also be noted that the nature of the stimuli of our study 
and of the previous studies assessing anxious individuals is not the same. 
Anxious individuals may find the threat-related stimuli aversive, and thus good 
attentional control may allow them to shift their attention from aversive stimuli; 
however, smokers may find smoking-related stimuli appetitive and attractive, 
thus they may not shift their attention from these stimuli, and may not show 
attentional avoidance to such stimuli. Such attentional avoidance is the 
characteristic of anxiety and may occur in response to threat-related stimuli, but 
not to smoking-related stimuli. Thus, it is probable that attentional control may 
act differently for smoking-related and threat-related stimuli. 
Methodological Considerations 
 
Except for the chapter on attentional bias and attentional control in 
relation to smoking (chapter 6), all other chapters are based on data from 
NESDA. Though we have already discussed several methodological issues in 
different chapters, here we will point out some limitations and strengths in 
NESDA in general. 
 
1. In the chapter on smoking age-onset and its association with 
psychopathology, we were unable to control for several potential 
confounding variables such as pre-existing drug and alcohol use and 
other confounding factors because data on age-onset of these variables 
were not available. 
2. In NESDA, one of the exclusion criteria was a primary diagnosis of a 
severe addictive disorder
116
, thus individuals with other addictive 
behaviors were excluded which might limit the generalizability of our 
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findings; however, at the same time, this is an advantage because our 
results were not ‘coloured’ with the effects of other substances. 
3. In NESDA, nicotine dependence was assessed only at baseline, and was 
not assessed in former smokers. 
4. NESDA may not be representative of other ethnic groups because the 
sample is pre-dominantly Dutch. However, for genetic studies, this is an 
advantage because studies have reported confounding ethnic differences 
in genotype and allele frequencies
117
. 
5. Depression and anxiety disorders are highly comorbid with other mental 
health problems, so the exclusion criteria of NESDA  to exclude 
persons who have a primary severe other psychiatric disorder, such as 
psychotic disorder, obsessive-compulsive disorder, bipolar depression, 
may limit the generalizability of our findings
118
. However, again, this is 
a merit for our research because comorbidity of severe other psychiatric 
disorders could also confound the link between smoking and 
depression-anxiety. 
6. Serum BDNF levels may not accurately reflect central BDNF levels, 
although previous animal research has shown a strong correlation of 
serum BDNF levels to cortical BDNF
119
. Moreover, results on serum 
BDNF cannot be generalized to the studies conducted on BDNF stored 
in plasma or platelets because plasma BDNF is circulated in platelets 
with 200 fold less concentration than serum BDNF. 
7. In our project on smoking-related attentional bias and attentional 
control, we did not manipulate nicotine deprivation, so urge to smoke or 
recency of smoking may have varied across smokers. Moreover, we 
recruited participants who smoked 10 or more cigarettes per day, thus, 
not controlling for variation in smoking behavior between light and 
heavy smokers. 
 
An advantage of addressing our research questions using NESDA data 
is that the sample size is fairly large, and we were able to control for a large 
number of variables/ covariates that may confound smoking-psychopathology 
association. Further, the sample is ethnically homogenous, and we focussed on 
psychiatric patients whereas most previous studies have used samples from the 
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general population. In psychiatric patients the prevalence of smoking is 
relatively high as compared to samples from general population. The NESDA’s 
assessment of depression and anxiety disorders were made according to DSM-
IV criteria, whereas most previous studies that investigated “smoking and 
depression-anxiety association”, assessed symptoms using self-report measures. 
 
The mechanisms underlying smoking-depression/ anxiety association 
can be better understood in longitudinal studies that follow healthy smokers over 
a span of several years. 
Clinical Implications 
 
The time to the onset of psychopathology in early-onset smokers was 
shorter than in late-onset smokers (chapter 2). As has been discussed already, 
starting smoking at a young age is associated with various adverse physical and 
mental health outcomes later in life. Thus, our findings and the previous 
research on early-onset smoking and worse health outcome, provides a reason to 
focus on children and adolescents in smoking prevention and cessation 
programs. 
 
Our finding that nicotine-dependent smokers experience more severe 
affective symptoms, and slower recovery of their symptoms as compared to non-
dependent smokers and non-smoking groups (chapter 3) suggests that chronic 
and heavy nicotine use does not help to alleviate negative affect, as is suggested 
by self-medication theory of addictive behaviors. This finding may be useful in 
educational programs for smokers who smoke in an attempt to control or self-
medicate their mood. These findings also suggest to implement a screening for 
nicotine dependence in health prevention and intervention programs in 
psychiatric patients who smoke. This may be helpful to develop more effective 
methods for managing depression and anxiety disorders, especially for those 
who smoke. 
 
In chapter 4, we found that among nicotine-dependent smokers, only 
those carrying the Val
66





have more severe symptoms of depression and anxiety as compared to non-
dependent smokers and the two non-smoking groups of former and never-
smokers. In Met
66
 carriers, however, no group differences in symptom severity 
among the four smoking groups were observed. This study implies that Val
66
Val 
carriers may benefit most from smoking cessation. Moreover, understanding of 
genetic influences on smoking-psychopathology association may be significant 
for guiding smoking prevention and intervention programs in identifying 
smokers, particularly those with nicotine-dependence who are vulnerable to 
adverse outcomes. 
 
Findings of chapter 6 imply that smokers low in attentional control may 
have hypervigilance to smoking-related cues, and may represent a risk group for 
smoking relapse. These smokers may benefit more from attentional bias 
modification (ABM) that aimed at strengthening attentional control and may 
reduce attentional bias for smoking-related stimuli, thus decreasing craving in 
addicted smokers, who may more likely to achieve abstinence and less likely to 
relapse to smoking. 
Future Research Directions 
 
This thesis has yielded important insights into future research on the 
association of smoking with depression or anxiety disorders.  
 
1. Our finding of an association of early-onset smoking with early onset of 
psychopathology (chapter 2) is consistent with the pre-clinical and 
clinical research on prenatal and early-age nicotine exposure. However, 
this was a cross-sectional study, therefore longitudinal and prospective 
research on the relationship of early-onset smoking with depression and 
anxiety disorder is needed to determine whether starting smoking early 
in life indeed explain the development of subsequent psychopathology. 
Moreover, longitudinal investigations should also focus on the 
underlying biological mechanisms explaining the association. Further, 
NESDA data on age-onset of several variables, such as pre-existing 
alcohol intake, drug use, or other substance use were unavailable. 
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Therefore, it is likely that these factors may influence the association, as 
research has shown that the onset of affective disorders is associated 
with other substance use as well
120
. Therefore, in future research on 
age-onset of smoking and the development of psychopathology, the role 
of these variables should be explored. 
2. More severe symptoms of affective disorders, and slower recovery over 
two-year period was observed in nicotine-dependent smokers than in 
non-dependent, former, and never-smokers (chapter 3); and when the 





Met carriers (chapter 4), we found that only those 
nicotine-dependent smokers have relatively more severe symptoms of 
depression and anxiety who carry the Val
66
Val genotype. In Val
66
Met 
carriers, no differences in symptom severity among the smoking groups 
were found. Thus, these findings suggest that genetic differences are 
important determinants to explain worse behavioral outcome of nicotine 
in some individuals but not in other. It would be interesting to replicate 
these findings in future research, and to investigate the role of other 
polymorphisms in BDNF gene and in other genes and smoking status 
on symptom severity in order to elucidate the underlying molecular 
mechanisms, and to help better our understanding of the complex 
association. Importantly, different ethnic groups should be given 
consideration in future research because of the ethnic differences in 
genotype and allele frequencies
117
. 
3. In current smokers, higher levels of serum BDNF were observed than 
the non-smoking groups of former and never-smokers who were 
comparable in their serum BDNF levels. No association of smoking 
severity, that is, nicotine dependence and number of cigarettes smoked 
per day, was found with serum BDNF levels. However, total smoking 
years was a predictor of serum BDNF (chapter 5). Whether quitting 
smoking has an effect on serum BDNF levels, could be studied in a 
prospective way to better understand the smoking-BDNF association, 
because research in this area is sparse. Similarly, it would be interesting 




4. Our finding of a relationship of low attentional control with high overall 
attentional bias and attentional bias to smoking-related pictures 
presented for 100 ms (chapter 6), suggests that the effect of attentional 
control on attentional bias is more prominent when stimuli are presented 
briefly. This indicates that in individuals with low ability to regulate 
attention, involuntary attentional capture by smoking-related cues is 
increased. This research can be extended by investigating the 
psychopharmacological mechanisms of attentional bias, taking into 
account attentional control. For example, attentional bias to smoking-
related stimuli had been reduced over time by attenuating dopamine 
levels in smokers by acute tyrosine and phenylalanine depletion
121, 122
. It 
would be interesting to explore the role of attentional control in this 
association. The brain activation associated with attentional bias to 
smoking-related pictures was reduced by decreasing the dopamine 
levels by administering the D2/D3 dopamine antagonist haloperidol
123
. 
This study can be extending by investigating group differences in the 
reduction or increase of attentional bias and related brain activation as a 
result of manipulating dopamine levels in smokers with low and high 
attentional control. Moreover, nicotine deprivation is associated with 
greater information processing bias
124
. Future research may be extended 
by experimentally manipulating craving to examine the effect of 
attentional control on the processing of these cues when there is an 
increased urge to smoke. However, as mentioned earlier, attentional 
control may function differently for appetitive stimuli, such as smoking-
related cues, and aversive stimuli, such as threat-related cues. 
Therefore, in future research, this issue should be taken into 
consideration. Moreover, attentional control can further be investigated 
as a linking mechanism of smoking-psychopathology association. 





To conclude, our findings provide an important insight into the complex 
association of smoking with affective disorders, and suggest that: 
 
1. The age at which an individual starts smoking might be an important 
factor to define the association of smoking with depression/ anxiety 
disorders, because the exposure to nicotine early in life may have 
detrimental effects on brain and behavior subsequently.  
2. The severity of the symptoms of an affective disorder depends on 
whether the smoker is nicotine-dependent.  
3. Genetic factors may play a role in smoking-psychopathology 
association. BDNF Val
66
Met polymorphism (and other genes/ 
polymorphisms) might moderate smoking-psychopathology association 
or may effect symptom severity in smokers and non-smokers. 
4. Serum BDNF may not be a possible linking mechanism underlying 
smoking-psychopathology association, because, on the one hand, the 
down-regulation of serum BDNF is associated with psychopathology, 
while, on the other hand, the up-regulation of serum BDNF is 
associated with smoking.  
5. Attentional control might be a possible linking mechanism underlying 
the association of smoking and depression/ anxiety disorders. However, 
research on attentional control and attentional bias to smoking-related 
stimuli should be replicated with large sample size and should be 
extended to investigate this in the context of smoking-psychopathology 
association. 
 
Our findings imply that it is crucial for smoking prevention and 
intervention programs to focus on children, and that public should be made 
aware of the detrimental effects of early-age nicotine exposure on brain and 
general health. This public awareness may lead to a reduction in smoking rates 
in children and adolescents. Further, understanding of genetic influences on 
smoking-depression/ anxiety association may help guide smoking prevention 
Chapter 7 
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and intervention programs in identifying smokers who may be more vulnerable 
to worse outcomes of nicotine use. 
 
Our findings also imply that attentional bias modification may be used 
to reduce smoking behavior in smokers with low attentional control. Reducing 
smoking behavior may have important positive consequences for negative 
mood. 
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De nadelige gezondheidsrisico’s/gevolgen van roken en van 
depressie en angststoornissen zijn goed gedocumenteerd, en deze 
aandoeningen doen zich vaak tegelijkertijd voor. Het doel van dit 
proefschrift was om ons inzicht te versterken in het verband tussen 
roken en depressie en angststoornissen, om mogelijke verklaringen te 
vinden voor dit verband, en om de gelegenheid te creëren om breder 
onderzoek te stimuleren naar het verband tussen roken en 
psychopathologie teneinde de onderliggende mechanismes van dit 
verband op te helderen. Dit zou rookpreventiestrategieën en 
interventieprogramma’s kunnen optimaliseren. 
Voor hoofdstuk 2 tot en met hoofdstuk 5 hebben we gegevens 
gebruikt van de Nederlandse studie naar depressie en angst (NESDA) 
en voor hoofdstuk 6 hebben we onze eigen gegevens verzameld met 
behulp van studenten van de Universiteit Leiden. 
 
Samenvatting van de bevindingen  
 
1. Eerst onderzochten we retrospectief het verband tussen leeftijd 
bij aanvang met roken en de leeftijd bij aanvang van de 
depressie en / of angststoornis (hoofdstuk 2). We selecteerden 
deelnemers bij wie een diagnose van een affectieve stoornis 
(depressie en/of angst) was gesteld nà aanvang met roken (N = 
1,055). Deelnemers werden ingedeeld in een vroege groep 
(begonnen met roken vanaf 10- tot 15-jarige leeftijd) en een 
late groep (begonnen met roken na 15-jarige leeftijd). De 
tijdsperiode tussen aanvang met roken en aanvang van de 
depressie en/of angststoornis was korter voor vroege beginners 
in vergelijking tot late beginners. Binnen de eerste vijf jaar na 
de aanvang met roken vertoonde een groter percentage vroege 
rokers dan late rokers de eerste tekenen van een affectieve 
stoornis. Toen we dit verband separaat onderzochten voor 
depressie en angststoornissen, vonden we dit patroon van 
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resultaten alleen voor angststoornissen. In de analyses werd 
gecorrigeerd voor de effecten van gender, opleiding en 
jeugdtrauma’s. 
2. Het effect van roken en nicotineafhankelijkheid op de ernst en 
tweejarig beloop van symptomen van depressie en angst werd 
onderzocht (hoofdstuk 3) bij patiënten met een actuele 
(afgelopen 6 maanden) diagnose van depressie en/of 
angststoornis (N=1,725). De steekproef werd ingedeeld in 
nooit-rokers, voormalige rokers, niet-afhankelijke rokers en 
nicotine-afhankelijke rokers. We ontdekten dat de symptomen 
van depressie, algemene angst, sociale angst en agorafobie bij 
baseline ernstiger waren bij nicotine-afhankelijke rokers dan 
bij niet-afhankelijke, voormalige en nooit-rokers. Deze 
verschillen bleven bestaan na correctie voor covariaten. Alleen 
op sociale angst verschilden de groepen niet langer na correctie 
van de modellen voor covariaten. Gedurende een follow up 
van twee jaar verbeterden de symptomen van depressie en 
angststoornissen bij nicotine-afhankelijke rokers minder snel 
dan bij de andere groepen, zelfs na controle op covariaten. 
Verschillen tussen de groepen in het verloop van symptomen 
van sociale angst en agorafobie werden tijdens het onderzoek 
niet gezien. Derhalve wordt bij psychiatrische patiënten roken 
in verband gebracht met ernstigere symptomen van depressie 
en angst, en met trager herstel, maar alleen als rokers nicotine-
afhankelijk zijn. 
3. De onderliggende mechanismen van het vastgestelde verband 
van roken en nicotine-afhankelijkheid met depressie en 
angststoornissen zijn onzeker. 
In hoofdstuk 4 onderzochten we de interactie tussen het BDNF 
gen Val
66
Met polymorfisme en rookstatus met de ernst van 
symptomen van depressie en angststoornissen. We 
selecteerden dezelfde NESDA steekproef, patienten met een 
actuele diagnose van een affectieve stoornis, en verdeelden die 
in nooit-rokers, voormalige rokers en rokers met en zonder 
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nicotine-afhankelijkheid. De resultaten lieten zien dat bij de 
patiënten met het Val
66
Val genotype van het BDNF Val
66 
Met 
polymorphism nicotine-afhankelijke rokers ernstigere 
symptomen van depressie en angst hadden dan niet-
afhankelijke rokers, voormalige rokers en nooit-rokers, terwijl 
de laatste drie groepen vergelijkbaar waren qua ernst van 
symptomen. Bij Met
66 
dragers waren er echter geen verschillen 
tussen de vier rokersgroepen qua ernst van depressie en angst. 
Aangaande de symptomen van sociale angst en agorafobie had 
het BDNF genotype geen effect. Nicotine-afhankelijkheid was 
de sterkste voorspeller van ernst van symptomen bij alleen de 
Val
66
Val dragers. Derhalve kan de relatie tussen nicotine-
afhankelijkheid en ernst van symptomen bij patiënten met een 




4. Zowel roken als psychopathologie worden geassocieerd met de 
concentratie van het eiwit BDNF (Brain-derived neurotrophic 
factor) in serum. In een poging om de mechanismen op te 
helderen onder het roken-psychopathologie-verband 
onderzochten we in hoofdstuk 5 de niveaus van serum BDNF 
in nooit-rokers, voormalige rokers en rokers met en zonder 
nicotine-afhankelijkheid, intussen controlerend op leeftijd, 
geslacht, opleiding, alcoholgebruik, lichamelijke activiteit, 
recente negatieve levensgebeurtenissen, BMI, het gebruik van 
antidepressiva en de diagnose van een affectieve stoornis. 
We onderzochten ook de interactie van het polymorfisme en 
rokersstatus met serum BDNF. We ontdekten dat rokers met 
en zonder nicotine-afhankelijkheid hogere niveaus van serum 
BDNF hadden dan de niet-rokende groepen van voormalige en 
nooit-rokers die vergelijkbaar waren in hun serum BDNF-
niveaus. De twee rokersgroepen met en zonder nicotine-
afhankelijkheid hadden vergelijkbare serum BDNF niveaus. 
Nicotine-afhankelijkheid en het aantal gerookte sigaretten per 
dag waren geen significante voorspellers van serum BDNF. 
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Het totale aantal rookjaren was dat echter wel. Derhalve was 
roken, ongeacht de zwaarte van het roken, geassocieerd met 
hogere serum BDNF niveaus. In tegenstelling hiermee was in 
NESDA onbehandelde depressie licht gecorreleerd met lagere 
niveaus serum BDNF. Dit tegenovergestelde patroon van 
verbanden voor BDNF maakt het niet erg waarschijnlijk dat 
het verband tussen roken en depressie wordt veroorzaakt door 
onderliggende BDNF mechanismen. 
Evenmin vonden we een interactie van BDNF genotype en 
rookstatus op serum BDNF, wat suggereert dat BDNF 
Val
66
Met polymorfisme niet verder bijdroeg aan het roken-
psychopathologieverband. In het geheel suggereren deze 
resultaten verder dat serum BDNF geen verbindend 
mechanisme is in het verband tussen roken en 
psychopathologie. 
5. Aandachtscontrole, het vermogen om zich te concentreren op 
taak-relevante stimuli, en om inmenging door aandacht-
afleidende stimuli te voorkomen, kan een ander potentieel 
mechanisme zijn in het verband tussen roken en 
psychopathologie. Tot nu toe is er geen studie die 
aandachtscontrole heeft onderzocht als een mechanisme onder 
het verband tussen roken en psychopathologie. 
 
Er is eerder onderzoek gedaan naar aandachtscontrole en 
attentional bias voor bedreigende informatie. Aangetoond is dat 
angstige individuen met een slechte aandachtscontrole minder goed in 
staat zijn om hun aandacht af te leiden van dreiginggerelateerde 
stimuli, en derhalve niet in staat zijn om met hun angst om te gaan. De 
eerste stap om de rol van aandachtscontrole in het verband tussen roken 
en psychopathologie te onderzoeken zou het onderzoeken zijn van de 
rol van aandachtscontrole in attentional bias voor aan roken 
gerelateerde signalen (hoofdstuk 6), omdat deze kwestie niet eerder 
aandacht heeft gehad. Aan roken gerelateerde attentional bias is 
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gerapporteerd in zowel de beginfase van oriëntatie als in de 
handhavingsfases van aandacht. 
Aandachtscontrole kan de aandachttrekkende effecten van 
afleidende informatie reguleren. In hoofdstuk 6 onderzochten we 
attentional bias in verschillende fases van informatieverwerking en de 
rol van aandachtscontrole in elk van deze fases door middel van een 
dot-probe test, met rook-gerelateerde en neutrale stimuli bij rokers en 
niet-rokers. De stimuli (foto’s) werden getoond gedurende 100 ms, 
500ms en 900 ms. De voornaamste bevindingen van de studie waren 
dat rokers een hogere overall attentional biasscore hadden dan niet-
rokers. Bij presentatietijden van 500 ms en 100 ms werden echter geen 
significante groepsverschillen gezien. In een langere presentatietijd van 
900 ms. was het groepsverschil in attentional bias een trend. Deze 
bevindingen suggereren een voorkeur in de latere fases van aandacht, 
maar niet in initiële oriëntatiefase. We vonden geen moderatie of 
interactie van aandachtscontrole met attentional bias voor deze stimuli. 
We vonden echter wel een sterke negatieve correlatie tussen 
aandachtscontrole met attentional bias voor aan roken gerelateerde 
stimuli die gedurende 100 ms werden getoond en met de overall 
attentional biasscore. Rokers met een beperkte aandachtscontrole 
hebben een hoge overall attentional bias en een attentional bias voor 
aan roken gerelateerde foto’s die gedurende 100 ms worden getoond. 
Dit suggereert dat het effect van aandachtscontrole op attentional bias 
prominenter is wanneer stimuli kort worden getoond. Zo’n negatieve 
correlatie werd echter ook gevonden voor niet-rokers wanneer stimuli 
werden getoond gedurende 100 ms. Derhalve geven de data aan dat bij 
individuen met een beperkt vermogen om aandacht te reguleren het 
onvrijwillig aandacht trekken door aan roken gerelateerde signalen (of 
andere in het oog springende signalen) wordt vergroot. De 
aanwezigheid van attentional bias voor aan roken gerelateerde stimuli 





De klinische implicaties van dit proefschrift leveren enkele 
aanbevelingen aan met betrekking tot stoppen met roken. Op jonge 
leeftijd beginnen met roken is geassocieerd met verscheidene fysieke 
en mentale gezondheidsproblemen in het latere leven.  De bevindingen 
in hoofdstuk 2 leveren een extra reden om preventie- en stop-
programma’s vooral op kinderen en adolescenten te richten. Verder kan 
de bevinding dat chronisch en veel roken niet helpt om negatief affect 
onder controle te houden (de zgn. zelfmedicatie theorie) (hoofdstuk 3) 
bruikbaar zijn in de voorlichting naar rokers die stoppogingen doen.  
De resultaten van hoofdstuk 4 impliceren dat Val
66
Val dragers het 
meest profiteren van stoppen met roken. Ten slotte impliceren de 
bevindingen in hoofdstuk 6 dat rokers met slechte aandachtscontrole 
hypervigilant zijn voor aandachttrekkende informative en dus een 
risicogroep vormen voor relapse na stoppen met roken. Deze rokers 
zouden kunnen profiteren van aandachtstraining (attentional bias 
modification (ABM)) teneinde hun aandachtscontrole te verbeteren en 
hun attentional bias te verminderen. 
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